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1.0 HIV in pregnancy and risk of transmission–background

ance between the mother’s own health needs, the need
to reduce vertical transmission and possible adverse effects of ART to the fetus. Newer data are reassuring with
regard to possible teratogenicity of ART but have produced new concerns over maternal and infant toxicity of
some drugs or HIV combinations.
The findings of the first RCT, published in 1994, showing that monotherapy with zidovudine (LDV) could reduce transmission from 25.5% to 8.3% in a non-breastfeeding population [5] have been supported by numerous
observational studies confirming this reduction in clinical practice [6–8]. More recent data continue to support
the efficacy of monotherapy with elective Caesarean section for certain women [9,10], and there are reassuring
data on the risk of resistance [11].
As standard treatment for non-pregnant adults is now
with at least three antiretrovirals, more women are taking combination therapy in pregnancy [3], although the
evidence for the efficacy of this approach, in reducing
mother-to-child transmission (MCT), comes from observational cohorts [4,10] and from the ACTG316 study of
the addition of nevirapine to standard combination therapy [12].
More women are now conceiving on antiretroviral
therapy (ART) and whilst it is not possible to produce
evidence-based guidelines that will address the management of every woman in this situation, Sections 6 and 7
cover much of the background data on efficacy and toxicity needed to make decisions in these more complicated scenarios. The protective role of Caesarean section
was demonstrated in both a meta-analysis [13] and a
RCT reported in 1999 [3,14], prior to the widespread use
of combination therapy in pregnancy. However, mounting observational data demonstrating very low levels of
transmission in women on therapy with undetectable viral loads who deliver vaginally, have led to changes in
the advice on mode of delivery for these women (see Sec-

The prevalence of HIV infection amongst women giving birth in England and Wales has increased every year
since 1990. Results from the Unlinked Anonymous Surveys of infection in pregnancy, show that in 2003, the
prevalence reached one in 180 (0.56%) in inner London, one in 271 in outer London (0.37%) and one in 1,282
(0.08%) in the rest of England [1]. The majority of these
women are from sub-Saharan Africa. The Department
of Health policy of recommending an HIV test to every
pregnant woman [2] has resulted in an increase in the
proportion of these women who are aware of their diagnosis prior to delivery (more than 80% in London in
2001) and a decrease in the absolute number of infants
infected in the UK [3].
In untreated women the risk of transmission is related to maternal health, obstetric factors and infant prematurity. Overall there is a close linear correlation between maternal viral load and risk of transmission but
rare transmissions have been reported even at plasma
viremia less than 400 RNA copies/mL [4]. CD4 counts
and clinical disease stage have been shown in some cohorts to have an association with the risk of transmission even after controlling for viral load. The only obstetric factors that consistently show an association with
risk of transmission are mode of delivery and duration of
membrane rupture, but invasive procedures in labor are
generally avoided as they pose a theoretical risk of iatrogenic transmission. Delivery before 34 weeks of gestation has been shown to be associated with an increased
risk of transmission.
There are still relatively few, and often conflicting data,
on the safety of antiretroviral therapy (ART) in pregnancy, and the management of any HIV-positive pregnant woman requires a careful consideration of the bal107
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tions 8 and 13) [15].
Formula feeding has been advocated for positive
women since breast-feeding was reported to result in
HIV transmission in 14% of at risk infants [16] and this
continues to be the BHIVA recommendation. Section 12
of these guidelines covers this issue in some detail, as it
is likely that further information about the risk of breastfeeding when mothers are on combination therapy, and
have undetectable viral loads, will become available,
making guidance in this area more complex in the future.
Women with HIV are at a small increased risk of adverse pregnancy outcomes such as spontaneous abortion, still-birth and intrauterine growth retardation [17].
Furthermore, an increased risk of premature delivery,
which has been reported with combination therapies [18]
has important implications for any treatment to reduce
vertical transmission.
New sections have been added on preconception, fertility, management of CIN in pregnancy and the transmission of hepatitis viruses in women with HIV coinfection.
The Guidelines are based on a review of the literature
and presentations at the major conferences. However, as
with previous versions, many of the recommendations
are based upon an understanding of HIV infection, data
from nonpregnant women and expert opinion. Each section has a highlights box. The section on management of
specific scenarios contains measures of the level of evidence and grades of recommendation.

2.0 Preconception and fertility management
in men and women infected with HIV
• Self-insemination of partner’s semen is recommended to protect the uninfected male partner of
an HIV-positive female and is easily performed by
the couple.
• Fertility assessment is indicated if conception has
not occurred after 6–12 months of self-insemination.
• Sperm-washing is recommended to protect the uninfected female partner of an HIV-positive male, but is
expensive, currently only provided by a few centers
and patient-funded in over 50% of cases.
There are three aspects to consider: interventions that
can minimize transmission risk between discordant couples during conception, the management of any fertility
issues and the state of health and medication of the infected partner preconceptually.
In discordant couples in which the male partner is infected with HIV, assisted conception with either sperm
washing or donor insemination is significantly safer
than timed unprotected intercourse and should be ad-
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vised in all cases. In these couples, presuming a stable
relationship, HIV transmission risk per act of unprotected intercourse is reported to be between 0.03% and
1% [13,19]. The risk can be reduced, but not eliminated,
by limiting exposure to the fertile period of the female
cycle. In the only prospective study of couples actually
trying to conceive through this method, 4% of women
seroconverted [20] which presents an unacceptable
risk. However, a retrospective study in Spain of 77 discordant couples conceiving in which the infected partner had fully suppressed HIV replication on therapy
for at least 6 months, reported no transmissions. The
couples were instructed how to limit unprotected intercourse to the fertile period of each cycle [21]. No data
were presented on seroconversion risk in discordant
couples that did not conceive and the numbers are too
small to comment on transmission rates but the study
does reflect common practice. Donor insemination removes the possibility of genetic parenthood from the
infected male but eliminates any risk of HIV transmission during conception. Sperm washing has the advantage of allowing genetic parenting and is a procedure
during which live sperm, which do not carry HIV, are
separated from HIV contaminated seminal plasma and
non-germinal cells by centrifugation before being used
in an insemination or IVF procedure [22]. The efficacy
of the wash is then verified with a post-wash HIV assay [e.g. polymerase chain reaction (PCR) or NASBA]
before being used in treatment [23,24]. The treatment
is relatively simple and significantly safer than timed
unprotected intercourse, with no reported cases of seroconversion in either female partner or child born in
over 3,000 cycles of sperm washing combined with intrauterine insemination, IVF or intracytoplasmic sperm
injection reported in the literature to date [22,23,25–29].
Couples should have natural cycle insemination unless
fertility factors are identified when fertility drugs for
superovulation or IVF should be considered. The disadvantage of sperm washing is that the treatment is at
present only provided by a limited number of fertility
centers in the UK, Europe and northern America. Until recently in the UK, the majority of cases had to be
funded by the patient. National Institute of Clinical Excellence guidelines published in February 2004 on fertility recommend sperm washing to be considered in
serodiscordant couples [30]. This has led to a significant
increase in the number of Primary Care Trusts willing
to fund up to three cycles of sperm washing treatment
on the basis of risk reduction (Gilling-Smith, personal
communication). A letter of recommendation by the
GU physician to the patient’s Health Authority is usually required. Couples should be provided with information and counselling on donor insemination and
sperm washing, including advice on how to access such
treatment to allow them to make an informed choice.
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Discordant couples in which the female partner is infected with HIV should avoid unprotected intercourse
and instead be provided with quills, syringes and sterile containers and advised on the use of self-insemination during the fertile time of the cycle. Fertility investigations should be initiated when pregnancy is not
achieved after 6–12 months of self-insemination, sooner
in women over 35 years or those with irregular cycles
or a history suggestive of tubal disease [24]. Concordant
couples should also avoid unprotected intercourse and
be advised to consider sperm washing to minimize the
risk of transmitting a viral variant to the female partner
and future child.
Although the ethics of offering fertility treatment to infected men and in particular women continues to be debated intensively [31–35], the increased life expectancy
and fall in vertical transmission risk noted over the last
decade has prompted fertility centers to review their policy. A recent UK audit indicated that 16% of men and 4%
of women attending HIV specialist clinics had enquired
about fertility treatment [36] and 30% of fertility centers
were planning to offer treatment to HIV-positive males
and 26% to positive females. In couples requiring reproductive assistance in the form of Human Fertilization
and Embryology Authority (HFEA) licensed treatment,
e.g. IVF, the HFEA Act (1990) requires treatment centers
to take into account the state of health of both prospective parents in terms of the welfare of any child arising as
a result of treatment. In ideal circumstances one would
recommend an undetectable viral load and CD4 count
4,400, no AIDS defining illness and, in the case of a positive female, a commitment to comply with interventions
during pregnancy and postnatally to minimize vertical
transmission risk. The referring HIV physician should be
asked to sign the Welfare of the Child form in preference
to the GP as he/she is likely to be best informed of ongoing high-risk activity and medical issues that might affect long-term health and viral transmission risk during
pregnancy [37].
Assisted reproductive techniques for infertility such as
IVF should at present only be offered within a research
setting, as little is known of the impact of invasive procedures such as intrauterine insemination, oocyte retrieval
and embryo transfer on the risk of vertical transmission [38]. Centers electing to treat HIV-infected patients
should have separate laboratory facilities to eliminate
the risk of cross contamination to uninfected samples
[24,34].
Guidelines for the fertility management of HIV discordant couples have been published by the British Fertility Society [39].

3.0 Sexual health of HIV-positive pregnant
women
• Routinely screen for genito-urinary tract infections at
presentation and in the third trimester.
• Repeat treponemal serology in the third trimester.
There are few data regarding the prevalence of genital infections in HIV-positive women in the UK [40]. At
present, the majority of pregnant HIV-infected women
in the UK come from, and mostly acquired HIV in, subSaharan Africa where the prevalence of genital infections, particularly in the HIV-infected population, can
be high [41]. In addition, recent figures from the Communicable Disease Surveillance Centre (CDSC) show a
small but significant increase in the number of patients
of Afro-Caribbean origin testing positive for HIV-1 in
the UK [42]. The prevalence of genital infections is high
in this ethnic group, and should these trends continue,
women of Afro-Caribbean origin will form an increasing
proportion of the antenatal HIV-positive cohort [43]. The
diagnosis and treatment of genital infections in any individual have clear benefits, both in terms of individual
morbidity and possible infectivity to any sexual partner.
In pregnancy, the welfare of the baby is an additional issue. However, apart from the recommendation that all
pregnant women should be screened for HIV, hepatitis
B virus and syphilis, asymptomatic pregnant women in
the UK are not routinely screened for genital infections.
Chorioamnionitis may lead to premature rupture of
the membranes with the possibility of premature birth
[44,45]. Chorioamnionitis, prolonged rupture of membranes and premature birth have all been associated
with MCT of HIV and may be interlinked [46–48]. Although both Chlamydia trachomatis and Neisseria gonorrhea
have been associated with chorioamnionitis, the organisms usually implicated are those associated with bacterial vaginosis (BV) and Ureaplasma urealyticum [44,45].
A strong association between BV and premature delivery has been reported [45,49]. There are data from Malawi that suggest that BV may be associated with an increased risk of maternal HIV infection in pregnancy as
well as premature delivery and MCT of HIV [50]. Further work is needed. A large meta-analysis assessing the
effects of antibiotic treatment of BV in pregnancy, does
not support the routine screening for and treatment of
BV in pregnant HIV-negative women [51]. However, the
available evidence cannot rule out a small benefit in pregnancy outcome associated with the screening and treatment of BV. As the numbers of HIV-1 infected women
are relatively small and the risk of screening and treating
for BV is small, the potential for increased MCT of HIV-1
in the presence of BV and the fact that HIV-positive
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pregnant women are recommended to undergo STD
screening, it seems reasonable to screen and treat for BV
in this high risk group.
It has long been recognized that genital infections, in
particular ulcerative diseases, are associated with sexual
transmission of HIV [52,53]. This may be due to an increase in local HIV replication resulting in a higher viral load in genital secretions, secondary to the presence
of specific organisms, and/or ulceration and inflammation [54,55]. Organisms associated with BV have been
shown to stimulate HIV expression in vitro [56,57]. A
study from Kenya demonstrated a reduction in cervical
mucosal shedding of HIV-1 RNA following treatment
of both gonococcal and chlamydial cervicitis [58]. Viral
load in cervico-vaginal specimens has been shown to be
correlated with MCT of HIV-1 [59]. Genital tract VL will
usually mirror the plasma VL [60], but there is increasing evidence of compartmentalization of HIV-1 between
the plasma and genital tract. Genital tract HIV-1 has been
detected in women with an undetectable plasma VL
[61,62], and genetic diversity of virus from the two compartments has been reported [63]. A number of factors
may be responsible for this, including differential drug
penetration into body compartments and the presence
of genital infections. At present, the majority of HIV-infected pregnant women in the UK deliver by pre-labor
Caesarean section, but increasingly those women with an
undetectable plasma viral load are undergoing a trial of
labor. In addition, women planning a pre-labor Caesarean section may rupture their membranes prematurely
which may result in a vaginal delivery. Thus, an increasing number of fetuses will be exposed to the cervico-vaginal secretions of HIV-positive women.
In the absence of randomized controlled trials, but for
the reasons outlined above, it would continue to appear
prudent to screen HIV-positive pregnant women for
genital infections. This should be done as early as possible in pregnancy and should be repeated at around 28
weeks. Syphilis serology should be performed on both
occasions. In addition, any infection detected should
be treated according to the UK national guidelines, followed by a test of cure [64]. Partner notification should
take place where indicated, to avoid re-infection.

3.1 Management of cervical intraepithelial neoplasia
(CIN) in pregnancy
An association between CIN, cervical cancer and HIVrelated immunosuppression has been known for many
years. Invasive cervical cancer has been an AIDS defining
illness since 1993 [65]. HIV is known to cause systemic
immune depletion which has been related to the development of CIN [66–69] and local immunosuppression,
which has also been related to the development of CIN
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[70]. The presence of HIV infection allows permissive
replication of human papillomavirus (HPV), which
tends to behave more aggressively and to be more resistant on a background of HIV disease [71]. There may be
an increased risk of rapid progression from CIN to cervical carcinoma [72].
With highly active antiretroviral therapy (HAART)
CIN tends to regress with rising CD4 count and falling
viral load [73,74].
Cytology should be undertaken in pregnancy as for
HIV-seronegative women. If an abnormality is detected,
referral should be made for colposcopy, which can be undertaken irrespective of gestation. If CIN is seen at colposcopy, it is customary to repeat the colposcopy on one
or two occasions during the pregnancy to ensure there
are no signs of invasive cancer developing. Usually, if
any abnormality is detected, treatment is deferred until 6 weeks postnatal, unless invasive cervical cancer is
suspected when biopsies will be required. Irrespective of
HIV status, it is prudent to do these in the operating theatre, since bleeding may be brisk.

4.0 Psycho-social issues
•
•
•

•

A thorough early assessment of the social circumstances of a newly diagnosed HIV-positive pregnant
woman is essential.
Consider special, tailored antenatal classes where inappropriate emphasis on breast-feeding and vaginal
delivery can be avoided.
All HIV-positive pregnant women should be encouraged to disclose their HIV status to their partner but this may be viewed as a process rather than
an event.
Testing any other children for HIV is recommended
but can often be deferred until after delivery.

Antenatal HIV testing of all pregnant women is clearly
an extremely effective medical intervention allowing
MCT of HIV to be reduced to low rates. However, the
intervention has to be completed within a finite time
period, the duration of which depends on the stage of
pregnancy when the diagnosis is made. HIV diagnosis
during pregnancy may be a profoundly shocking and
life-changing experience for the newly diagnosed HIVpositive woman. There may be a complex mix of emotional, psychosocial, relationship, economic and even legal issues that arise directly out of the HIV diagnosis.
The newly diagnosed woman also has a relatively brief
time in which she needs to be able to develop trust in her
medical carers and attain sufficient medical knowledge
of her situation to be able to make appropriate informed
decisions that will affect the long-term health of herself,
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her fetus and her male partner. For many pregnant
women the psychological impact of an antenatal HIV diagnosis is similar to that of bereavement, with the additional anxiety about the possibility of the HIV being
passed on to her child [75,76].
The prevention of MCT can only be achieved if the
pregnant woman embraces the medical interventions appropriately, and in a number of cases the psychosocial issues may threaten to impede or obstruct the medical process of reducing MCT. These issues, therefore, need to
be understood by those providing antenatal HIV care, so
that potential problems may be identified and addressed
early, and their impact minimized.
4.1 The antenatal HIV team
Antenatal HIV care should be delivered by a multi-disciplinary team (MDT). The members of the team providing care for different HIV-positive pregnant women will
vary according to the needs of the individual women and
her circumstances. The minimum team would comprise
an HIV specialist, an obstetrician, a specialist midwife, a
pediatrician and the recommendation of peer and voluntary sector support. Frequently, it may be necessary to
involve many others; including patient advocates, social
workers, legal advocacy, clinical psychologists, psychiatrists, counsellors, health advisors, CAB (Citizens Advice Bureau) workers, interpreters, the voluntary sector, community midwives, clinical nurse specialists and
health visitors [77]. In addition to managing the clinical care of HIV-positive women these MDTs are ideally
placed to oversee the delivery of antenatal HIV care at a
more strategic level, including the uptake and delivery
of HIV antenatal testing protocols, training of antenatal staff, clinical governance and strategic development
of antenatal HIV services. In settings with relatively few
HIV-positive pregnant women it is still important to develop robust pathways of care with identified members
of an MDT. Regular links, formal or informal, could then
also be established with a larger unit to provide advice
and support as necessary. Good communication is vital in view of the complexity of the issues involved and
care planning should be pro-active and instigated early
so that any significant problems can be identified early
and addressed in the limited time available. A rapid and
thorough early assessment of the social circumstances
of a newly diagnosed HIV-positive woman is a critical
part of this process. The likely nature of the adjustment
to the HIV diagnosis and a woman’s attitudes to the recommended interventions should also be assessed early.
Clear referral pathways to relevant members of the multidisciplinary team should be established, ideally to identified individuals in the different specialties. This allows
for the individuals of the team to develop the necessary

expertise and improves communication and understanding within the team. Patients who initially refuse interventions or default from outpatient follow-up need to be
identified and actively followed up with particular care.
Efforts should be made to understand the reasons for
these problems in order that they can be addressed in a
supportive manner by the team, but with some urgency
if that is required. The management of these women
should be reviewed regularly, ideally in the context of
regular team meetings.
4.2 Expectations of pregnant women
These will obviously vary from individual to individual
but pregnancy is frequently a time of high expectation,
anxiety and concern. Pregnant women may report that
their pregnancy is treated as though it is public property and feel closely scrutinized by those around them.
They may also carry the burden of expectations of their
partner, family and friends. Many of these shared expectations will revolve around ‘natural birth’ (i.e. vaginal delivery), breast-feeding and the avoidance of all
medications during pregnancy. Levels of disclosure of
their HIV status to those around them will vary enormously. Some women will not have disclosed their
HIV-positive status to anyone, including their partners,
while others may have disclosed to a few key individuals only [78].
Many pregnant women engage in antenatal classes,
but these generally concentrate on issues such as vaginal
delivery and breast-feeding, and they seem to be rarely
used by HIV-positive women. In centers with sufficient
levels of antenatal HIV activity, specially tailored antenatal classes may be worthwhile so that the particular issues around HIV and pregnancy can be discussed in an
informed, safe and supportive environment.
4.3 Peer support
Peer support by trained peer support workers is an invaluable component of the management of HIV-positive
pregnant women. Many newly diagnosed HIV-positive
pregnant women are initially reluctant to engage with
peer support, whether one-to-one or in a group setting.
However, the great majority of women who do engage
with it find that peer support becomes one of the most
highly valued of all the interventions that they undertake. Peer support is an integral component in the process of providing effective antenatal HIV care. It becomes particularly relevant in cases where the women
have multiple psychosocial concerns, and fear or reluctance in agreeing to uptake of recommended MCT interventions [79].
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Peer support is also helpful in addressing issues
around their HIV status, and helping to facilitate disclosure of HIV status. Some centers have established antenatal/perinatal support groups for HIV-positive pregnant women and these have proved to be very popular
and useful for those involved (Innovative Vision Organization, London, UK, unpublished communication). Dedicated peer support workers can also pick up issues such
as problems with adherence to medication. It is important to develop good working relationships with peer
support workers so that appropriate training and governance can be maintained.
4.4 Disclosure of HIV status to healthcare workers
The importance of informing appropriate healthcare
workers should be emphasized to each HIV-positive
pregnant woman and encouraged. This includes midwives, GPs, health visitors and pediatricians. The process of in-patient care should be explained clearly so that
the women can be helped to inform ward staff explicitly about levels of disclosure to visitors, and to reassure
them that they will be treated in the same way as HIVnegative women.
4.5 Disclosure of HIV status to partners
Levels of disclosure of newly diagnosed pregnant
women about their HIV status to their partners varies
from 30% to 75% depending on the setting [77,80,81].
This issue may cause considerable distress to newly diagnosed women and frequently requires time and support from services, including midwives, doctors, peer
support workers, counsellors and health advisors. Disclosure should be encouraged in all cases but may be
viewed as a process that may take some time [82,83].
Different strategies may need to be developed to facilitate this process in individual cases. However, the situation in the UK is becoming more complex in the light of
recent legal cases leading to criminal prosecutions following HIV transmission. One of the cases is currently
under appeal and the legal status of HIV transmission is
still uncertain. This is not the place to analyse this issue
in detail as the legal framework is still developing. However, clinicians are advised to keep up to date with developments in this area [84]. Non-disclosure to a sexual
partner, especially in the context of antenatal HIV testing, is important for several reasons. A significant number of the male partners of women testing HIV-positive
during antenatal testing will be HIV-negative at the time
of initial diagnosis. Some issues relating to HIV serodiscordant couples are discussed below. There are situations where a newly diagnosed HIV-positive woman refuses to disclose to a current sexual partner, or appears to
want to delay disclosure indefinitely. This can give rise
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to very complex professional, ethical, moral and potentially, legal situations. There is a conflict between the
duty of confidentiality to the index patient and a duty
to prevent harm to others. Breaking confidentiality in order to inform a sexual partner of the index patient’s positive HIV status is sanctioned as a ‘last resort’ by both the
WHO, GMC and BMA [85–87]. However, it is not to be
taken lightly as it could have the negative impact of deterring others from testing due to fear of forced disclosure and loss of trust by patients in the confidential doctor–patient relationship. This could then undermine the
current successful high uptake of antenatal HIV testing.
It is important to accurately record discussions and disclosure strategy in difficult cases.
Difficult disclosure cases should be managed by the
MDT. This allows consideration of different approaches
and a shared responsibility for the process. In practice, it
is usually possible to achieve disclosure without breaking confidentiality and there are a variety of potential
approaches depending on the individual case. The first
priority in these cases is to understand why the index
patient refuses to disclose. This may be due to a straightforward fear of HIV combined with a lack of acceptance
and an inability to come to terms with their HIV diagnosis. They may fear rejection, violence, homelessness,
and be dependent on their partner economically, or for
their current legal status as a dependent [88]. They may
be more concerned about bringing shame on their family and/or themselves if their diagnosis becomes known
more widely. HIV infection is still highly stigmatized in
many communities. Index cases may also be concerned
that the mere fact that they were diagnosed first means
that they will be blamed for the infection by their partners, if they are also found to be HIV-positive, regardless of the reality of the situation. These issues can be discussed with the patient and addressed supportively. It is
accepted that this process may take some time and it is
important that the patient is encouraged to protect their
partner from infection while disclosure is being considered [89].
Simultaneous partner testing during the original antenatal HIV test should be encouraged wherever possible as couples will frequently choose to receive their HIV
test results together, providing simultaneous disclosure.
The term ‘Reverse Discordance’ has been used to describe the situation during antenatal HIV testing where
the pregnant woman is HIV-negative and her male partner is found (simultaneously) to be HIV-positive [77].
This knowledge clearly has a variety of benefits, especially giving the fact that acute HIV sero-conversion in
pregnancy, or while breast-feeding, is likely to significantly increase the risk of vertical HIV transmission [90].
Disclosure of HIV status to a regular male partner in the
context of the antenatal HIV testing of pregnant women
is important for several reasons: the health of the male
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partner if he is HIV-positive and unaware of his status,
the prevention of ongoing HIV transmission, and to ensure that the male partner is aware of the medical and
treatment issues concerning the fetus. Many of those initially reluctant to disclose feel relief once they have removed that burden. However, others may experience
adverse results as a direct result of disclosure, including
domestic violence, rejection and homelessness, and need
to be supported through this [91].
4.6 Disclosure of HIV status to others
Reassurance about confidentiality is extremely important, especially regarding family members and friends
who may not know the diagnosis but are intimately involved with the pregnancy. Women from communities
with high levels of HIV awareness may be concerned
about HIV ‘Disclosure by Association’ when discussing
certain interventions including taking medication during pregnancy, having a Caesarean section, and avoiding breast-feeding. Possible reasons such as the need to
‘take vitamins’, or having ‘obstetric complications’ and
‘mastitis’ may help the women feel more confident in explaining the need for certain procedures to persistent enquiries [92].
4.7 HIV serodiscordance and antenatal HIV testing
Between 20% and 80% of newly diagnosed HIV-positive
pregnant women may have partners who are HIV-negative, depending on the setting [77,80,93]. This has significant long-term implications for the provision of care for
these couples beyond the management of the pregnancy
alone. It is important to help couples understand some
of the possible biological reasons for HIV discordance
and the importance of preventing subsequent infection
of the negative partner [94–97]. Condom use should be
discussed in detail but it should be recognized that there
are relatively high levels of unprotected intercourse between HIV-serodiscordant partners. Information concerning post-sexual exposure prophylaxis should be discussed with the couples [98–102]. It is most likely to be
appropriate for couples using condoms exclusively, who
then have occasional condom ‘accidents’. However, detailed studies in this setting are lacking [103]. (For further
information see the British Association for Sexual Health
and HIV National Guidelines for the use of post exposure prophylaxis for HIV following sexual exposure:
www.bashh.org/ guidelines/ceguidelines.htm).
4.8 Welfare and immigration
Many HIV-positive women will have issues relating to
social support needs and/or immigration issues. In both

cases it is important to identify the issues as early as
possible so that women can be referred for appropriate
specialist advice and support. Dispersal is an issue that
arises and is generally felt to be inappropriate in pregnant women, especially if they are late in pregnancy or
are recently delivered [104].
4.9 Formula feeding support
Women with very limited funds should have access to
supplementary formula feed [105].
4.10 HIV testing of existing children
This issue should be raised with all newly diagnosed
pregnant women who have other children. The timing
of testing may vary depending on the individual situation but the issues should be explored early and a strategy clearly identified and recorded.
4.11 Adherence to ART
This is of vital importance for the success of therapy and
pregnant women may need extra support and planning
in this area, especially if there are practical or psychosocial issues that may impact adversely on adherence. Referral to peer support workers, psychology support and
telephone contact may all be considered.
4.12 Eligibility for treatment
Legislation concerning eligibility to Free NHS Health
Care in the UK is currently changing, both in primary
and secondary care. It is not yet clear how this will affect
antenatal care generally (including access to routine antenatal HIV, STS and hepatitis screening) as well as the
antenatal care of identified HIV-positive women. Clearly
it would be regarded as unethical and undesirable to
deny an HIV-positive woman in the UK with the treatment and interventions that would preserve her own
health as well as protect her child from becoming vertically infected. Indeed, a recent unpublished letter from
the Department of Health implies that full antenatal care
should be given to all pregnant women presenting in the
UK irrespective of their immigration status. In the absence of formal guidance it would seem inappropriate to
withhold treatment and to deal with each case on a caseby-case basis. Of more concern is the fate of undiagnosed
HIV-positive pregnant women who are unable to access antenatal care and have their screening tests. These
women may present in labor without knowing their HIV
status. Rapid [e.g. point-of-care (POCT)] HIV testing in
this setting should be encouraged [106]. This is an area
that is changing so it is necessary that people involved
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in antenatal HIV care stay up to date with developments.
It may be advisable to get advice from colleagues, the
GMC, BMA and Medical Defence Organizations in difficult cases. Legal advice can also be sought from organizations such as the THT (http://www.tht.org.uk).
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4.14 Resistance to intervention
Some women may choose to refuse any intervention during pregnancy or declare their intention to breast-feed
the baby against advice. These cases are best dealt with
by a team approach. It is important to engage with these
women as sensitively as possible as often the reasons for
refusal may be obscure initially but will eventually turn
out to have relatively straightforward solutions. Common reasons may include fear of accepting their HIV status, religious reasons, fear of disclosure or partners and
other family members, forbidding the woman from embracing interventions. Some women are afraid that treatment will lead to disclosure, either by HIV medications
being found in their possession, or ‘Disclosure by Association’ as mentioned earlier. Exploring these issues at
length will often lead to solutions that may need to be
improvised somewhat to meet the needs of the individual case. In cases where the women still refuses intervention and threatens to breast feed against advice it may
become a child protection issue once the child is born.
These cases are rare but would need to be discussed with
Social Services predelivery so that a strategy can be developed.
4.15 Postnatal issues
Postnatal depression is relatively common in the general
population and tends to be under-diagnosed. It is certainly a risk in HIV-positive women and needs to be actively excluded as a diagnosis, especially where women
may already be depressed, isolated, homeless or have
economic, psychosocial and/or immigration and legal issues. Dispersal of HIV-positive pregnant women,
or those recently delivered, may also be a risk factor.
Women with, or at risk of, antenatal depression should
be assessed early and referred to: psychology/mental health teams; peer support; ‘Surestart’ where available or other local projects (not necessarily HIV-related)
available for new mothers and their children.
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5.0 Viral load and resistance
•
•

4.13 Referral pathways
Women should be given the opportunity to discuss a
care plan in detail and this should include referral pathways as appropriate.

et al. in

•

Viral load is an important determinant of transmission.
Quantify HIV plasma load (i) at least every 3 months
and at week 36 in women on established therapy, (ii)
2 weeks after starting or changing therapy, (iii) at delivery.
Use a second assay where there are discrepancies between viral load, CD4 count and clinical status.

5.1 HIV viral load
The risk of MCT correlates with maternal plasma viral
load even among women receiving ART [107–109]. Although the risk is greatest for those pregnant women
with high viral loads, transmission can occur even when
maternal viral loads are below the lower detection limit
of the assay [110–112]. Although there is no evidence for
a threshold below which transmission will not occur,
low or undetectable maternal viral loads are associated
with very low rates of transmission to the infant. Studies have generally demonstrated correlation between viral load in plasma and cervicovaginal secretions [60,113];
however, viral load may sometimes be higher in the genital tract than the blood and virus may even be shed in
this compartment when plasma viral load is undetectable [62]. Responses to ART and selection of drug-resistant variants may differ between plasma and CVS [114]
and there is evidence of genetic diversity between viral
populations in the blood and female genital tract that
could account for this [115,116].
Consequently, plasma viral load may not always reflect activity of HIV in the genital tract and this could account for those rare cases of transmission in women with
low or undetectable plasma viral load. More information
is required to determine whether there is a need for monitoring genital tract viral load as part of routine clinical
management [111].
Plasma viral load should be monitored at least every
3 months during pregnancy and at approximately 36
weeks gestation (depending on turn around time) in order to inform decisions on mode of delivery and treatment of the infant. Knowing that the viral load at delivery was undetectable will be reassuring to all concerned.
A number of commercial assays are available for quantification of HIV-1 RNA, the most widely used in the UK
being the Bayer HIV-1 RNA 3.0 branched chain DNA
(bDNA) assay and the Ultrasensitive Roche Monitor RT
PCR assay. Although the Bayer bDNA assay generally
gives lower HIV RNA copy numbers than the Roche RT
PCR (version 1.5) the two assays correlate well [117].
Absolute HIV RNA copy number may vary not only
with the assay employed but also with biological varia-
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tion of RNA and specimen handling [118]. The contribution of these variables to HIV RNA concentrations appears to be of the order of 0.3–0.6 log10 copies/mL. In order to ensure reliable and accurate quantification of HIV-1
RNA the same assay should be used to monitor viral load.
In the UK, 78% of HIV infections among women attending antenatal clinics are with non-B subtypes,
61% being subtype A and 29% subtype C [119]. Accurate quantification of non-B subtypes of HIV-1 is therefore an important requirement for monitoring pregnant
women. Mismatches between primers and probes used
in some commercial assays and RNA target sequences
may occasionally result in falsely low or undetectable viral loads among individuals infected with divergent subtypes [120–122]. In cases where there are discrepancies
between viral load, CD4 cell number and clinical status
it is advisable to re-test with another assay in which different nucleotide sequences are used to bind or amplify
target RNA.
5.2 Antiretroviral drug resistance
•
•
•
•
•

Determine HIV genotype (or phenotype):
pre-therapy (at presentation)
if viremic on established therapy
at delivery if on monotherapy
2–3 weeks after stopping suppressive therapy

Antiretroviral drug resistance will develop when viral replication continues under the selective pressure of
drug exposure, as can occur with suboptimal treatment,
and drug resistance is one of the major factors responsible for treatment failure. Genotypic and phenotypic assays for detection of resistance to antiretroviral drugs
are available commercially. Conventional phenotyping
assays involve culturing isolates of HIV in the presence
of drug and determining the concentration of drug required to inhibit the virus. More rapid recombinant assays are also available in which reverse transcriptase and
protease sequences amplified from plasma RNA are inserted into a laboratory clone in which these genes have
been deleted; the recombinant virus then being assayed
for drug susceptibility. The most recent development in
technology is the ‘virtual phenotype.’ This provides a
quantitative prediction of phenotype from the genotypic
sequence using a database containing paired genotypic
and phenotypic data. Genotyping assays use PCR amplification of the reverse transcriptase and protease genes
followed by automatic sequencing of the viral DNA. The
antiretroviral drug resistance profile is obtained by identification of mutations known to be associated with resistance. However, the results generated are complex and
expert interpretation is required.

Genotyping tends to be used more widely than phenotyping as it has a faster turnaround, is technically less demanding and is more cost effective. In general, sequence
based genotyping assays require at least 1,000 HIV RNA
copies/mL and samples with low viral loads may not be
sequenced successfully. Current commercial assays are
based on population sequencing and will not detect minority species representing less than about 20% of the viral population. Such minority drug resistant variants may
persist and impact on future treatment options. There is
therefore a need for more widespread availability of single genome sequencing assays that are more sensitive
than standard genotyping systems [123]. Drug-resistant
virus quickly reverts to wild type in the absence of drug
pressure consequently resistance testing should be conducted on samples obtained while the woman is still on
treatment, including use of archived samples.
As with viral load assays, commercial resistance assays have been developed using the B subtype of HIV
and non-B subtypes may, therefore, be amplified and sequenced less efficiently. Although information is more
limited on patterns of drug resistance among non-B subtypes, particularly among infected pregnant women, it
has been demonstrated that the frequency and pattern of
mutations are generally similar to subtype B [124–127].
The protease gene of HIV is highly polymorphic and this
may contribute to development of resistance to protease
inhibitors (PIs). Naturally occurring accessory mutations
within the protease gene have been demonstrated in 85%
of individuals never treated with PIs and the frequency
of these mutations has been shown to be higher among
non-B than subtype B virus [128]. Individually these accessory mutations, which reflect natural polymorphisms,
have limited effects on drug susceptibility; however, they
may influence the rate at which resistant virus is selected
during treatment with PIs [129]. The clinical significance
of this, particularly for individuals infected with non-B
subtypes of the virus, is unclear.
Transmission of drug resistant virus is well documented,
with prevalence rates among newly infected drug-naive individuals of 10–20% in Europe and North America [130–132]. Among untreated individuals with chronic
infection, prevalence rates are generally lower, reflecting
earlier infection or reversion of drug-resistant mutants to
wild-type in the months following transmission. BHIVA
guidelines for the management of HIV in adults recommend HIV genotypic testing of all patients at presentation.
With more widespread use of ART, both before and
during pregnancy, there is concern that drug resistance
could limit its efficacy in reducing perinatal transmission
risk as well as compromising the future treatment op-
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tions for the woman. More information is now becoming available on development of antiretroviral drug resistance during pregnancy [133]. Although treatment
with zidovudine monotherapy has been recommended
during pregnancy since 1994, there has been concern
that this may be more likely than combination treatment to lead to the emergence of drug-resistant virus. A
number of genotypic mutations within the reverse transcriptase gene (codons 41, 67, 70, 210, 215, 219) can occur within a few months of initiating zidovudine monotherapy and mutations at codon 215 are associated with
high level resistance. In the ACTG 076 trial the prevalence of any mutations associated with decreased susceptibility to zidovudine was only 3% and no mutations
at codon 215 were detected [134]. Similarly, no mutations
were detected among women in the Côte d’Ivoire receiving short course zidovudine monotherapy initiated late
in pregnancy [135]. A more recent UK study [11] also
demonstrated that resistance to zidovudine was uncommon (5%) and restricted only to those women treated before 1998 who had higher baseline viral loads than those
treated between 1998 and 2001. Although other studies have demonstrated zidovudine-associated resistance
mutations in approximately 10–25% of pregnant women,
with high level resistance at codon 215 in 6–12% [136–
139], maternal viral loads were generally higher and
exposure to zidovudine more extensive than among
women in whom prevalence rates were low. The risk of
developing zidovudine resistance is, therefore, likely to
be low if monotherapy is restricted to drug naive asymptomatic women, with low viral loads and good CD4 cell
numbers (see Section 6).
Genotypic testing is recommended before starting zidovudine monotherapy and at delivery to con.rm that
the circulating virus has remained wild type. In contrast
to zidovudine, high-level resistance to lamivudine can
develop rapidly as only a single point mutation in the
reverse transcriptase gene at codon 184 (M184 V) is required. In a small UK study [140] four of five women
(80%) treated with zidovudine and lamivudine from the
second trimester had developed the M184 V mutation at
the time of delivery or very shortly after. A larger French
study [125], with samples from 132 women, demonstrated lamivudine resistance in 52 (39%) when lamivudine had been added to zidovudine after 32 weeks gestation. There was no evidence of resistance to lamivudine
when treatment was for less than 4 weeks duration. A US
study [141], which tested 207 delivery samples, demonstrated lamivudine resistance in 44% of drug experienced
women receiving standard combination ART. Factors associated with development of the M184 V mutation in
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all studies included higher viral load, low CD4 cell number and longer duration of therapy.
Rapid emergence of high-level resistance to the nonnucleoside reverse transcriptase inhibitor (NNRTI) nevirapine can occur due to single point mutations in the reverse transcriptase gene most frequently at codons 103
(K103N) and 181 (Y181C) as well as at codons 106, 108,
188 and 190. The long half-life of nevirapine also contributes to development of resistance. In the Ugandan HIVNET 012 study [142] drug-naive women received a single
dose of nevirapine at the onset of labor and their infants a
single dose within 72 hours of delivery. Nevirapine resistance was detected in 19% (21/111) of women at 6 weeks
post partum and was associated with higher baseline viral loads and lower CD4 cell numbers [143]. Detectable
resistance appeared to be transient, with these mutations
no longer found in plasma 12–24 months post-partum.
More recent studies have demonstrated resistance in as
many as 40% of women following single dose nevirapine [144]. Following single-dose nevirapine resistance is
more frequently detected in women with subtype C HIV
infection compared with subtypes A and D [145]. Resistance to nevirapine can also occur when a single dose is
given to women already receiving combination antiretroviral treatment, the prevalence of the K103N mutation
being approximately 15% [141]. The implications of resistance following single-dose nevirapine are discussed
in Section 6.
Genotypic resistant mutations will affect the replicative
capacity or fitness of the virus but the significance of this
in terms of HIV transmission is still unclear. Transmission of drug-resistant virus to the infant can occur [146].
Among infected children the prevalence of zidovudine
associated resistance mutations, as a result of perinatal
transmission, has ranged from 9% to 17% in some studies [138,139,147], and between 30% and 40% in others
[125,148]. Similarly, nevirapine-resistant virus was detected in 11 of 24 (46%) infected infants in the HIVNET
012 study [143]. However, mutations were transient and
no longer detected 4–12 months after delivery. The implications of these mutations and there subsequent ‘fading’ for the further management of these children is uncertain. Although some studies have indicated that drug
resistance is not necessarily associated with an increased
risk of perinatal transmission [134,137,138,147], there is
still insufficient information to define clearly the relationship between drug-resistant mutants and MCT.
Any pregnant woman on non-suppressive antiretroviral therapy (ART) should have a resistance test conducted [149,150]. Following short-term ART to prevent
MCT (START), a genotypic analysis should be performed
early in rebound.
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6.0 ART in pregnancy: efficacy
•
•
•

•
•

•
•

•
•
•

See individual scenarios.
Balance the risk of HIV transmission with the toxicities of therapy.
Zidovudine monotherapy remains a valid option
for women: (i) with <6–10 000 HIV RNA copies/
mL plasma; (ii) wild-type virus; (iii) not requiring
HAART for maternal health; (iv) not wishing to take
HAART during pregnancy; (v) and willing to deliver
by PLCS.
Do not prescribe dual NRTI therapy.
Prescribe effective (.3 drug) combination therapy whenever: (i) indicated for maternal health as
per adult guidelines; (ii) baseline maternal viremia 410,000 cp/mL; (iii) baseline maternal viremia
<10,000 cp/mL (as an alternative to ZDV mono-therapy plus pre-labor Caesarean section).
Drug resistance detected on genotype/phenotype.
Short-term HAART (START) for prevention of MCT
should: (i) be discontinued after delivery when viral
load <50 cp/mL; (ii) carefully consider the half-life
of each component to avoid unplanned monotherapy after stopping, especially drugs with a low genetic barrier to resistance.
Avoid stavudine plus didanosine as NRTI backbone
when ever possible (and monitor lactate if unavoidable).
HAART commenced prior to conception should usually be continued throughout pregnancy.
Consider a detailed anomaly ultrasound at 21 weeks
for all fetuses exposed to ART during the first trimester.

Twenty compounds are currently licensed by the Medicines Control Agency for the specific treatment of HIV-1
infection in the UK. Of these only zidovudine is specifically indicated for use in pregnancy (excluding the first
trimester) to prevent MCT of HIV.
The introduction of recommending HIV testing to all
pregnant women and the increasing number of women
of child-bearing potential aware of their HIV infection
who are on combination therapies and wishing to conceive has led to a significant increase in the number of
women needing advice on the management of HIV in
pregnancy. Between 2002 and 2003 19% of known HIVpositive pregnant women in the UK and Ireland had
conceived on combination ART [151]. At preconception consultation or some weeks into the first trimester
of pregnancy such women will wish to know whether
they should interrupt, continue or change therapy. The
difficulty for the physician is that few studies have ad-

dressed current practice. The Cochrane Systematic review which was restricted to interventions shown to be
effective in randomized controlled trials, concludes that
zidovudine monotherapy, nevirapine monotherapy and
delivery by elective Caesarian section (PLCS) appear to
be very effective in decreasing the risk of transmission
[152]. Whilst true this does not reflect current best care.
In this section we will summarize key efficacy data from
observational and controlled studies (Tables 1a and 1b).
Section 13 described various scenarios and weighted recommendations on the use of ART in pregnancy that balance the needs of the mother and infant with the limitations of the available data are presented. The question
of efficacy relates to reducing infections in the neonate,
maintaining or improving maternal health and preserving maternal therapeutic options. Pre-clinical and clinical safety data can be found in the appendix.
6.1 Nucleoside analog reverse transcriptase inhibitors
(NRTIs)
The efficacy of zidovudine to reduce MCT of HIV-1 has
been demonstrated in several large randomized controlled studies [5,108,153] and supported by epidemiological surveys [6–8,154]. The efficacy of zidovudine
ranges from 67%, when started before the third trimester administered by IV infusion during labor and given
to the neonate for the first 6 weeks of life, to 50% with
shorter courses (started at week 36) without a neonatal component, in non-breast fed babies, to 30% with a
similar regimen in breast-fed babies [155,156]. In a nonbreast-feeding population, the transmission rate with addition of zidovudine has been reduced to 6–8% [5,8]. As
with monotherapy in non-pregnant women zidovudine
transiently reduces HIV-1 plasma viremia and increases
CD4-positive lymphocyte counts. In ACTG 076, in which
mothers commenced zidovudine 100 mg five times daily
between weeks 14 and 28 of gestation, therapy was associated with a 0.24 log10 reduction in plasma viremia at
the time of delivery [8,112]. In the Bangkok study, zidovudine 300 mg twice daily was commenced at week 36
resulting in a 0.57 log10 reduction in plasma viremia at
delivery. This was considered to account for 80% of the
efficacy of zidovudine to reduce transmission [108].
Viral load is an important predictor of transmission
and zidovudine reduces transmission at all levels of maternal viremia. However, in mothers with very high viral
load (4,100,000 RNA copies/mL) the transmission rate
may be 460% and, therefore, even with a two-thirds reduction in transmission the risk to the infant would still
be around 20%. Additional measures are, therefore, re-
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quired for these and probably for any mother with a viral
load 46–10,000 copies/mL (no transmissions occurred in
the recent Thai short course zidovudine plus single dose
nevirapine study when maternal viral load was less than
6,000 HIV RNA copies/mL plasma at the time of delivery [Communicated at 11th Conference on Retroviruses and
Opportunistic Infections, February 8–11, 2004, San Francisco, CA, USA, LB41] with only one transmission out
of 387 exposed if maternal baseline HIV RNA copies
<25,000/mL [157]). PLCS has been demonstrated to reduce transmission by as much as zidovudine (see Section 7). When zidovudine and PLCS section were combined, in a cohort of women with all levels of viral load,
transmission was further reduced to <1% [14]. In a South
African randomized open-label study of 362 mother–
infant formula-feeding pairs (A1455-094), didanosine
alone was compared with stavudine alone, zidovudine
alone and with didanosine combined with stavudine. Although all three ddN arms resulted in greater viral load
reductions than zidovudine only the combination arm
(4.6%) had equivalent transmission rates to zidovudine
monotherapy (5.6%) [158]. Transplacental transfer stavudine is similar to that of zidovudine and lamivudine
with equivalent levels found in maternal plasma and
cord blood after oral and IV dosing [159]. Studies in pigtailed macaques show fetal blood levels of dideoxyinosine to be half the maternal plasma level [160]. Stavudine
and didanosine appear to accumulate in amniotic fluid
[159,160].
6.2 PIs
PIs are highly protein-bound and placental transfer
in humans appears to be limited. In a safety, tolerability and efficacy study of 86 pregnant women ritonavir
mono-therapy was initiated at gestation week 36 at a
dose of 300 mg bd increased incrementally to 600 mg bd
by day 15 and taken for a mean of 20 days. The median
viral load reduction was 2.8 log10 and the transmission
rate was 9.5% but 12 women discontinued treatment, 10
because of elevated liver enzymes (see Section 7) [161].
6.3 NNRTIs
The rapid placental transfer and long half-life of nevirapine have led to studies of the efficacy of nevirapine to reduce the risk of MCT of HIV. In HIVNET 012 two doses
of nevirapine, the first given to the mother in labor and
the second to the neonate age 48–72 hours, were compared with zidovudine initiated in labor and prescribed
to the neonate for 1 week. Transmission was reduced
by 47% with nevirapine after 3 months follow-up [142].
As with short-course (4 weeks) zidovudine in the same
setting, the transmission rates at 18 months remain less

than expected (15.7% cf. 25.8%), the increased protection
with nevirapine persisting even though the infants were
breast-fed [162]. In the SAINT study transmission rates
at 8 weeks with the HIVNET 012 study regimen (14%)
were not significantly different from the rate of transmission in mother-infant pairs receiving zidovudine 300
mg plus lamivudine 150 mg in labor and twice daily to
mother and infant for 1 week post-partum (10.8%) [163].
The efficacy, low cost and ease of use led to the widespread use of the two-dose nevirapine regimen in resource-restricted settings and it’s adoption by the World
Health Organization (WHO), although these have now
changed.
6.4 Maternal health
Monotherapy is used to reduce the risk of MCT of HIV.
Although these and other guidelines do not recommend
monotherapy when ART is required for maternal health
in two studies a maternal survival benefit was seen following 4 weeks of zidovudine monotherapy compared
with placebo [164,165].
In a multicenter study of 40 newborns, zidovudine plus
lamivudine was well tolerated and associated with an
HIV transmission rate of 2.5% (95% CI 0.1–13.2%) [166].
In a large French prospective non-randomized cohort
study of 440 women treated with initially with zidovudine, with lamivudine added from gestational week 32,
maternal plasma HIV viremia was reduced by 0.95 log10
and the MCT rate was 2.6%. This compares favorably
with a historical transmission rate of 6.5% in mothers
in the same cohort receiving zidovudine monotherapy
[125]. In an international randomized controlled study
in breast-feeding women there was a 22% reduction in
transmission at 18 months follow-up compared with placebo in children perinatally exposed to zidovudine plus
lamivudine from 36 weeks gestation to 1 week post-partum, although this did not quite reach statistical significance [167]. Equivalent efficacy between short-course
stavudine combined with didanosine compared with zidovudine and between zidovudine combined with lamivudine compared with single dose nevirapine was noted
above. The current practice, as advocated by the WHO
in resource-limited settings [168], of adding single dose
nevirapine to short-course zidovudine (from 34/40),
which in practice constitutes serial monotherapy with a
short overlap at the time of delivery, reduces transmission to 2% in formula-feeding mothers [157].
6.5 Combinations with more than two drugs
In the North American Women and Infants Transmission Study (WITS) cohort there has been a reduction in
transmission from 7.8% in mother–infant pairs receiving
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zidovudine monotherapy to 1.1% in mother-infant pairs
exposed to triple therapy including a PI [4]. In PACTG
367 the transmission rate among 3081 pregnant women
delivering in North America has fallen from 4.2% in 1998
to 0.5% in 2002. Among women who did not receive any
ART transmission was 18.5%, falling to 5.1% with zidovudine monotherapy, 1.4% with dual NRTIs and 1.3%
with three or more drugs. Of the 1,736 women who had
plasma viremia of less than 1000 copies/mL at the time
of last measurement prior to delivery the transmission
rate was 0.7%. This includes an unspecified number of
transmissions when maternal viremia was less than 50
copies (data communicated at 11th Conference on Retroviruses and Opportunistic Infections 2004, but not in the abstract). Unfortunately in the recent analysis of the WITS
cohort transmission rates for triple therapy, which included a NNRTI, were not separated from dual therapy
exposure and thus cannot be compared either with dual
therapy or with other triple therapies [4]. In the ACTG
316 study nevirapine was added at labor to maternal
therapy whether it was mono, dual or triple and a further dose was given to the neonate. The 1.5% transmission rate among the 1,174 mother–infant pairs, which
was considerably less than anticipated at study design
(5%), confirms the potency of current management strategies. Forty-nine percent of mothers had no detectable
plasma viremia at delivery. The study was closed when
it became clear that it was not powered to demonstrate
any benefit from nevirapine used in this way [12].
6.6 Maternal health
The development of mutations associated with resistance following monotherapy is considered in Section 5
above. There is now evidence that single-dose nevirapine does impact on the future response to NNRTI containing regimens. In the Thai PHPT-2 study, NNRTI-Resistance mutations were detected in 30.5% of women 12
days after single-dose nevirapine. Triple therapy with
nevirapine, stavudine and lamivudine in a fixed dose
combination pill was commenced a mean of 5.8 months
later. After 6 months treatment 86% of women not previously exposed to nevirapine had suppressed viremia to
<400 HIV RNA copies/mL plasma compared with 68%
of women with a history of single dose nevirapine exposure. Using <50 copies/mL as a measure of therapeutic
success 75% of nevirapine unexposed mothers had no detectable plasma viremia at 6 months compared with 34%
of mothers who had a history of detectable NNRTI mutation following single dose nevirapine exposure. Furthermore, mothers exposed to nevirapine in whom NNRTI
mutations had not been found post-partum also faired
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less well than unexposed mothers with only 53% achieving <50 copies at 6 months [169].
Efavirenz has not been used in this way, but has a
plasma half-life that is at least as long as nevirapine and
similar problems might be anticipated.
In London, women starting triple ART following zidovudine monotherapy were no less likely to have fully
suppressed viral replication during 30 months follow-up
post delivery than women treated with triple combinations during pregnancy [170].
Where therapy is not required during pregnancy for
maternal health, combinations of three or more drugs to
suppress HIV replication may be prescribed short term
to reduce transmission and it is to be hoped to preserve
future maternal therapeutic options. However, different
drug half-lives are being found to impact on combination therapy, too. In the UK and elsewhere stopping nevirapine or efavirenz 5–7 days prior to nucleoside analogs
or switching to a drug with a short clearance time is recommended. Following only a few weeks of drug exposure, nevirapine plasma concentrations remain above
the IC50 of wild-type virus for up to 10 days with considerable individual variation [171] and even out to 21
days [169]. Similar drug persistence has been reported
with efavirenz [172] with evidence of racial differences.
This observation is supported by the discovery of higher
efavirenz concentrations in patients of black African or
Hispanic origin compared with those of white European
origin. Different polymorphism frequencies in CYP2B6
at G516 seemingly underlie this association [173]. However, nevirapine resistance mutations have been detected
by population-based sequencing in women post-partum
despite full suppression of plasma viremia, triple therapy and a tailored approach to discontinuing therapy
[174].

7.0 ART in pregnancy: toxicity
7.1 Maternal toxicity
Information about the safety of drugs in pregnancy is
limited. Data are usually from animal studies, anecdotal
experience, registries and clinical trials. This section aims
to summarize the current data available on the shortterm toxicity of ART during pregnancy.
Physiological changes that occur during pregnancy
may affect the kinetics of drug absorption, distribution,
metabolism and elimination, thereby affecting the drug
dosing. During pregnancy, gastrointestinal (GI) transit
time becomes prolonged; body water and fat increase
throughout gestation and are accompanied by increases
in cardiac output, ventilation, and liver and renal blood
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flow; plasma protein concentrations decrease; renal sodium reabsorption increases; and changes occur in metabolic enzyme pathway in the liver.

and no reasonable alternatives.

7.2 NRTIs

Hyperglycemia, new onset diabetes, exacerbation of existing diabetes mellitus and diabetic ketoacidosis have
been reported with administration of PIs [179,180].
Women taking ART that includes a PI reportedly have a
higher risk of developing diabetes mellitus during pregnancy (3.5%) than HIV-negative women or HIV-positive
women taking either NRTIs or on no therapy (1.35%) (P
0.025) [181].
In a study of 86 HIV-positive, treatment-naive women,
ritonavir monotherapy commenced in the 36th week of
pregnancy was not well tolerated and 12 women stopped
treatment (10 due to elevated liver enzymes; one due to
severe vomiting, diarrhrea, headache and fever; one an
inability to take the capsule). The most frequently reported maternal adverse events included diarrhrea (30),
nausea (22), altered taste (15) and vomiting (10). There
were 51 maternal grade 3/4 laboratory abnormalities
(mostly elevated liver enzymes) [161].
The plasma concentrations of saquinavir when prescribed as unboosted soft-gel capsules are generally low
[182] but when either the hard-gel capsules [183] or softgel capusles [184] are boosted by coprescription with
ritonavir plasma concentrations appear to be generally
therapeutic and the combination well tolerated.
Ritonavir boosted lopinavir also appears well tolerated and clinically effective although a pharmacokinetic
study showed significantly reduced drug exposure in
pregnancy.
The use of PIs in combination therapy has been reviewed in 89 pregnancies, from six sites in the USA. 36
women received nelfinavir, 33 saquinavir, 23 indinavir and five ritonavir. Obstetric complications reported
were one full placenta previa, two abruptions, four oligohydramnios, three pre-eclampsia and one spontaneous abortion. PIs were generally reported to be well tolerated and appeared safe in pregnancy [185].
An evaluation of 64 HIV-infected pregnant women receiving three or more antiretrovirals including a PI in
27, nevirapine in 22 and combinations of a PI with nevirapine in 15 women also found combination therapy to
cause few side effects. Maternal drug related complications included: nevirapine: rash (three), hepatitis (one);
PI: vomiting (two), ureteral obstruction (one) [186].

Nucleoside analog drugs are generally well tolerated in
pregnancy; reported incidences of adverse effects are
similar to those reported in non-pregnant HIV-infected
individuals. In the French cohort, most of the adverse
events seen in mothers taking zidovudine plus lamivudine were related to pregnancy or post-partum complications of pregnancy [125]. A retrospective Swiss report
evaluated the pregnancy outcome in 37 HIV-infected
pregnant women treated with combination therapy; all
received two NRTIs and 16 received one or two PIs [175].
Almost 80% of women developed one or more typical
adverse effects of the drugs such as anemia, nausea/
vomiting, raised transaminases, or hyperglycemia.
Nucleoside analogs may cause mitochondrial dysfunction as they have varying affinity for mitochondrial DNA
g polymerase. This affinity can result in interference with
mitochondrial replication, resulting in mitochondrial
DNA depletion [176]. The relative potency of the nucleoside analogs in inhibiting mitochondrial DNA g polymerase in vitro is highest with zalcitabine, followed by
didanosine, stavudine, lamivudine, zidovudine and abacavir [177]. Toxicity related to mitochondrial dysfunction
has been reported in patients receiving long-term treatment with nucleoside analogs and although this generally resolves with discontinuation of the drug or drugs,
fatalities have been reported.
Early in 2001, the US Food and Drugs Administration
(FDA) and the European Medicines Authority advised
doctors that they had received reports of three pregnant women who had died of lactic acidosis following
treatment with stavudine and didanosine (as part of triple therapy) and a further four cases of lactic acidosis
in pregnancy with this combination [178]. It is not clear
whether the frequency of this recognized complication
is higher in pregnant than non-pregnant women. In one
London center lactic acidemia (one with acidosis) with
deranged liver enzymes has been documented in two of
five women taking stavudine, didanosine and nevirapine. Both recovered following discontinuation of therapy. No cases were documented in a further 28 women
taking other triple therapy combinations (G Taylor, personal communication). Monitoring liver function and
blood lactate in pregnant women on this combination is,
therefore, recommended. The use of didanosine plus stavudine in pregnancy should be restricted to woman with
resistance or intolerance to other nucleoside analogs

7.3 PIs

7.4 Nevirapine
The use of nevirapine as part of combination ART was
retrospectively reviewed in a London cohort of 46 HIV-

122

infected pregnant women. Thirty initiated nevirapine
during pregnancy, 16 in the second trimester and 14 in
the third. Nevirapine was usually well tolerated and the
only adverse effects probably related to nevirapine were
rash (two) and biochemical hepatitis (two). Six women
developed GI symptoms, which were attributed to, and
settled on changing, the nucleoside analogs [187]. However, a number of hepatitis-related deaths have been reported in pregnant women taking regimens that include
nevirapine [188]. There has also been a change to the
Summary of Product Characteristics (February 13, 2004)
which, along with other changes, now states that ‘women
and patients with higher CD4 counts are at increased risk
of hepatic adverse events, often associated with rash, especially women with pretreatment CD4 counts greater
than 250 cells/mm’ [3]. Although there is no specific
mention of pregnancy, pregnant women are perhaps
more likely to match this description than non-pregnant
women, especially those choosing short-course therapy.
Whether the risk of hepatitis is the same in pregnancy is
uncertain. Bershoff-Matcha and colleagues report no serious adverse events among 43 pregnant women compared with 23 among 227 non-pregnant women [189],
whereas in PACTG 1022 four of 17 women discontinued
nevirapine due to toxicity compared with one of 21 randomized to nelfinavir. One patient treated with nevirapine, whose baseline ALT was 58 U/L, died of fulminant
hepatic failure [190]. Mooney et al. reported ‘major’ toxicities in five of 56 women (10.5%) taking nevirapine during pregnancy compared to one episode of renal calculi
among 47 women taking a PI (2%) [191]. Natarajan found
a relatively low rate (4.7%) of nevirapine complications
among 189 pregnant women in London with most occurring when women started therapy with a CD4 count
greater than 200 cells/mm [3] but not above 250 cells/
mm [3,192]. This could be explained by the lower CD4
counts seen with hemodilution in pregnancy. In a study
of 126 women commencing nevirapine-based HAART
in Thailand, eight (6.3%) developed hepatitis of whom
six discontinued nevirapine and nine (7.1%) developed
a rash resulting in the discontinuation nevirapine in six.
No statistically significant difference in frequency of
complications was seen in the women commencing nevirapine-based HAART with a CD4 count greater than 250
cells/mm3 (14.5%) compared with those starting at less
than 250 (12%), but the treatment time was shorter in the
later group who started therapy at 28 weeks of gestation
[193]. 9.4% of a Thai population (males, pregnant women
and non-pregnant women) starting nevirapine as part of
triple therapy developed liver or skin toxicities with not
significantly higher rates in pregnant women with CD4
counts greater than 250 cells/mm [3,194]. These con-
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flicting data are likely to be due to difference in populations, small sample size and reporting bias especially if
the outcomes for patients starting therapy during pregnancy are mixed with patients continuing therapy during pregnancy. It is interesting that in the Kisumu study
in Kenya in which zidovudine, lamivudine and nevirapine are started at 34 weeks gestation to prevent MCT in a
breast-feeding population, 13 of 155 (8.4%) mothers had
to stop nevirapine with Grade 2–4 toxicities, but a CD4
count cut-off of 250 cells/mm [3] did not discriminate
between susceptibility states [195].
Nevirapine has been widely prescribed and effective
in pregnancy. In terms of experience only nelfinavir (as
the third drug on a dual NRTI backbone) has been used
to a similar degree. There is very little experience with
other triple therapies in pregnancy. All the studies have
shown combination therapy to be effective in reducing
MCT and, therefore, the potential benefits of the intervention must be assessed against the risk of toxicity. Prescribing in pregnancy, particularly when initiating therapy, should be with due caution. The pharmacokinetics
in pregnancy of newer agents such as abacavir, emtricitabine, tenofovir, atazanavir and fosamprenavir have not
been described. A reduced dose of didanosine is usually
prescribed with combined with tenofovir, but there is increased renal excretion of didanosine in pregnancy. Although not considered sufficient to merit dose amendment, there are no data on didanosine in pregnancy when
prescribed with tenofovir. However, the new European
recommendations are that these compounds should not
be co-administered, especially in patients with high viral load and low CD4 cell count (Letter to Health Care
Professionals from Bristol-Myers Squibb and Gilead,
March 2, 2005). Total nelfinavir concentrations are commonly lower in pregnancy, dose adjustment may be necessary but studies of the protein-unbound concentration
and a correlation of pregnancy pharmacokinetics data
with efficacy are required. There is an urgent need for
extensive investigation of the pharmacokinetics of antiretroviral therapy in pregnant women to ensure efficacy,
reduce toxicity and to prevent the emergence of resistance through inadvertent under dosing. Consider theraputic drug monitoring (TDM) for all new agents and
all PIs.
7.4.1 Pregnancy outcome
In a study of 76 women taking a PI as part of combination therapy during pregnancy there were 15 pre-term
deliveries (PTD) (o37 weeks) but 60% of the mothers had
identifiable risk factors for PTD such as a history of PTD,
smoking and substance misuse. HIV transmission had
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been excluded in the 34 babies with adequate follow-up
[196].
The possibility that PI usage was associated with an
increased risk of PTD had been suggested by Swiss investigators in 1998 [175] following which recruitment of
women to studies of PIs in pregnancy was temporarily
suspended. Among 462 women participating in ACTG
studies in 1998–1999 the PTD rate was 20% but with no
significant difference between women exposed to PIs and
those not exposed to PIs (RR 0.7 95% CI 0.5–1.1), whilst
the rate of very premature delivery (<32 weeks) was less
among women taking PIs (RR 0.2; 95% CI 0.05–0.8). Nineteen of 462 (4.1%) babies were born with a structural abnormality [197]. An increased rate of PTD has also been
reported in women on combination ART with PIs in Europe [198]. In the latest analysis of this ongoing study, a
trend towards more preterm deliveries (in women not
delivering by PLCS) has been shown over time, correlating with increased use of combination therapies [199].
However, this was not seen in a North American cohort
[200] nor on analysis of data submitted voluntarily to
the Antiretroviral Pregnancy Register, which mostly includes submissions from North America. A trend to very
low birth weight was, however, noted in babies exposed
to three or more drugs in utero [201]. Data from the UK
and Ireland of 3,807 pregnancies reported between 1990
and 2003, show that 13% of deliveries were before 37
weeks with a 1.5-fold increased risk if the mother took
HAART during pregnancy compared with zidovudine
monotherapy [151].
7.5 Other drug treatments
Women on ART are commonly on other therapies. In a
multicenter retrospective study of 148 infants exposed
to ART in utero the risk of congenital malformation was
significantly raised in those exposed in the first trimester to folate antagonists used for Pneumocystis pneumonia prophylaxis combined with ART [202]. In addition to
neural tube defects, first trimester exposure to folate antagonists has been associated with an increased frequency
of cardiac and renal tract malformations. The therapeutic
needs of all women of child-bearing potential should be
regularly reviewed particularly now that PCP and other
prophylactic therapies can be safely discontinued as immune function recovers. Regular administration of even
small doses of folic acid (such as found in some multivitamin preparations) appears to negate this additional
risk [203]. An association between gestational diabetes
(GD) and PI used in pregnancy has also been proposed.
In a Spanish cohort of 609 pregnant women with HIV
infection the incidence of GD was 7% (higher than expected for the general population). Older age and use of
PI (OR 2.3 95% CI 1.0–5.3) were associated with GD in a
multivariate analysis [204].

8.0 Obstetric management of pregnancy and
delivery
•

•
•
•
•
•
•
•
•
•
•

In addition to any obstetric considerations PLCS is
recommended for:
- all women taking ZDV monotherapy,
- women on combination therapy with detect
able viremia,
- women with HIV/HCV coinfection.
PLCS to prevent MCT should be planned for 38
weeks. Elective vaginal delivery is an option for:
- women with no detectable viremia.
Maternal wishes should be considered.
Avoid invasive monitoring of fetus and artificial
rupture of membranes.
Prescribe appropriate peri-operative antibiotics for
all CS and immediately should membranes rupture
during first stage of labor.
Give corticosteroids for threatened preterm delivery.
Communication between team members is essential and each delivery (by whatever mode) should be
planned.
Ensure provision of appropriate formulations of neonatal therapy on the delivery/postnatal ward.
Give the mother a written care plan with contact details for emergency admissions.
Advise ART for invasive genetic diagnostic tests.
IV zidovudine is NOT usually indicated for mothers
not on ZDV or for mothers with <50 HIV RNA copies/mL plasma on HAART.

8.1 Management of pregnancy and delivery-obstetric issues
The management of the HIV-positive pregnant woman
during the delivery of her baby aims to minimize the risk
of MCT while not increasing maternal and neonatal morbidity.
A decision on mode of delivery will involve the mother
and her physician in a detailed risk assessment. Discussion will take into account maternal plasma viral load,
efficacy data on mode of delivery by pre-labor C-section
(Table 2), the use of ART in pregnancy and very importantly the wishes of the mother.
8.2 Viral load
Initial studies proposed that a pre-labor Caesarean section (PLCS) in the presence of intact membranes reduced
the risk of vertical transmission. A trans-Atlantic metaanalysis of 15 prospective cohort studies [205] and a randomized controlled study of mode of delivery in Europe.
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[14] both supported the protective effect of PLCS, this effect continued even when ART was used. In the RCT,
there was an overall reduction in transmission of 70%,
in a cohort of women with all levels of CD4 and disease
status. These studies showed, however, that Caesarean
sections performed in labor or after membrane rupture
were not associated with the same reduction in MCT.
Indeed in a further meta-analysis of the 15 cohorts, the
risk of transmission increased approximately 2% for every hour of rupture of the membranes up to 24 hours
[206]. These studies, done before routine viral load testing and combination ART, showed a consistent reduction in MCT with a PLCS. Whether this protective effect
continues when the maternal HIV 1 RNA is very low or
undetectable has yet to be established.
Several studies have looked at MCT rates according to
maternal viral load. In a study of 480 mother-child pairs
there was no MCT among 84 women with HIV-1 levels
below 500 copies/mm [3] at booking or among the 107
women with undetectable levels at delivery [207]. In a
similar study there was no MCT in 57 women with a viral load of less than 1,000 copies/mm [3,107]. However,
transmission has been reported when maternal viremia
was not detected [112,208]. A recent meta-analysis of
seven prospective studies from the USA and Europe revealed 44 transmissions in 1020 deliveries where plasma
viral load was <1,000 HIV RNA copies/mL at or around
delivery. The rates were lowest for mothers on ART. In
multivariate analysis transmission was lower with ART,
Caesarean section, greater birth weight and higher CD4
count. These data, collected when HIV-RNA PCR assays
were less sensitive than currently, suggest a protective
effect of both ART and Caesarean section even at very
low viral loads [111]. Whether Caesarean section in the
presence of combination ART and undetectable plasma
viremia (<50 HIV RNA copies/mL plasma) continues to
offer a protective effect is unknown.
There have been several studies that have suggested
that the complications from Caesarean section are higher
in HIV-positive women, with the highest risk in those
women undergoing emergency Caesarean section. The
main complication appears to be post-partum fever and
this was increased in women with low CD4 counts. However, in at least one of these studies, 16% of the women
had not been on any ART, only 82% received ‘peri-operative’ antibiotics (amoxicillin or mezloxicillin plus a blactamase inhibitor), and the mean CD4:CD8 ratio was
0.49 in the patients who had postoperative complications
[209–211]. Many of these studies were performed before
the recommendation that prophylactic antibiotics be prescribed to all women undergoing Caesarean section to
reduce infectious morbidity [212].
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A more recent case-controlled study from the UK where
all the HIV-positive women were treated with ART therapy in pregnancy and all received prophylactic antibiotics showed no difference in the incidence of post-operative morbidity [213]. Recent data from Latin America
and the Caribbean revealed much lower rates of postpartum morbidity in HIV-positive women, the majority
of whom (73%) were taking HAART. Following vaginal
delivery (265 cases) and pre-labor, prerupture of membranes elective Caesarean section (240 cases) the complication rates were 3.4 and 3.3%, respectively [214].
In the standard pregnant population, it is recommended
that PLCS be performed at 39 weeks to reduce the frequency of transient tachypnoea of the newborn seen in
babies delivered by PLCS [215]. However, in the HIVpositive group of women, for whom delivery by Caesarean section has been decided it is suggested that this be
performed at 38 weeks to avoid the potential risk of labor
or membrane rupture, the frequency of which will necessarily increase toward term.
Mode of delivery must be discussed with the woman
and her wishes taken into account. In addition to factors
such as the viral load and the use and duration of use
of the ART obstetric factors should also be considered.
Many units in the UK now have Caesarean section rates
of 25%, if there are obstetric factors that make it seem
likely that the HIV-positive woman has an increased
chance of an emergency Caesarean section, e.g. a large
baby with an unengaged head, it may be wise to plan a
PLCS rather than risk the complications of an emergency
Caesarean section.
Intrapartum management in the HIV-positive parturient is also complicated by the need to avoid fetal blood
sampling, invasive fetal monitoring and rupture of the
membranes. Scalp laceration has been reported with
the ventouse, forceps should be the assisted delivery instrument of choice. The use of IV zidovudine, as per the
ACTG076 regimen, is not considered essential in women
on triple therapy with <50 HIV RNA copies/mL plasma.
Data from the French Perinatal Cohort show no additional benefit of intrapartum IV zidovudine if the viral
load is less than 1,000 HIV RNA copies/mL plasma [216].
8.3 Other pregnancy issues
8.3.1 Prenatal diagnosis
HIV-infected women completing invasive prenatal diagnosis should be counselled in a specialist fetal medicine
unit and the best non-invasive screening tests available
should be employed in the first instance. In those women
requiring genetic amniocentesis, every effort should be
made to avoid inserting the needle through the placenta.
Administration of ART to cover the procedure is advised
although there are no data on transmission rates with or
without ART.

Women who become unwell during pregnancy with
signs and symptoms of pre-eclampsia, obstetric cholestasis or other liver dysfunction may have a pregnancy-related problem but consideration should be given to the
adverse effects of the ART. Studies in the UK [217] and
Spain [218] but not Brazil or South Africa [219,220] have
reported low pre-eclampsia rates in HIV-1-infected
women untreated or treated with monotherapy but normal rates when combination therapy is used. Any woman
presenting with vomiting and malaise should be investigated for acidosis, hepatitis and pancreatitis. If there is a
lactic acidosis, consideration should be given to discontinuing the ART even at this critical time.
8.3.2 Management of nausea and vomiting
Nausea and vomiting is common in early pregnancy.
Symptoms occur between weeks 6 and 16 but may continue into the second and third trimester in about 20% of
patients. The incidence of nausea and vomiting may be
increased in women taking ART. Most women are able
to adjust the timing of their ART to avoid times of nausea. In most cases, the nausea and vomiting can be managed without any intervention. However, in some cases
the women may require antiemetics to control severe
vomiting. If oral preparations cannot be tolerated, injections or suppositories can be used. Anti-histamines such
as promethazine and cyclizine have been widely used
in pregnancy. There is no conclusive evidence to suggest that therapeutic doses of these drugs are associated
with increased risk of congenital abnormalities above the
background rate for the population [221,222]. Prochlorperazine and metoclopramide should be considered as
second line agents as there are less data on their use in
pregnancy, and they have been associated with extrapyramidal reactions in some young women [221,222]. There
is very little information on the safety of ondansetron in
pregnancy. Pyridoxine may be effective at reducing nausea, however, in some cases it is less effective at reducing
vomiting. There are limited published data on efficacy
and safety to recommend using ginger to control nausea
and vomiting.
Hyperemesis gravidarum is a condition defined by intractable vomiting leading to fluid and electrolyte disturbances and nutritional deficiency. Symptoms usually occur during the first month of gestation and remit by the
end of the first trimester. Most patients will require hospital admission for fluid, electrolyte and vitamin replacement. Controlled interruption of therapy may be the best
option in some cases. There are no known interactions
between antiemetics and antiretrovirals.
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9.0 Pregnancy in women with HIV-2 infection
•
•
•
•
•

If mother asymptomatic, good CD4 (4300), possibly
manage as low viral load HIV-1.
If HIV-2 viral load known to be <50 cp/mL antenatal/peripartum/neonatal intervention may be unnecessary.
If mother symptomatic, low CD4 (o300) manage as
low CD4 HIV-1.
Do not prescribe NNRTIs.
Breast-feeding probably best avoided.

HIV-2 is endemic in West Africa and other areas of high
prevalence include parts of India and Portugal. Eightyseven cases of HIV-2 infection had been reported in the
UK; 72 diagnosed with HIV-2 infection only and 15 with
HIV-1 and HIV-2 coinfection [223]. Thirty-nine of the 72
HIV-2 infections are in women. HIV-2 appears to be less
pathogenic than HIV-1 with prolonged periods of asymptomatic infection and slower rates of disease progression
reflecting a lower rate of viral replication [224,225]. MCT
rates of HIV-2 are also low, 0–4% in breast-fed infants, in
the absence of any interventions [226–228]. To date, interventions to reduce transmission of HIV-2 in pregnant
women have not been clearly defined.
Treatment is indicated in pregnancy if the woman is
symptomatic and CD4 cell numbers are <300 per mm
[3] as this is usually associated with a detectable viremia [229]. NNRTIs have little inhibitory activity against
HIV-2 and are, therefore, not recommended but the virus
is susceptible to NRTIs and some PIs. Decreased in vitro
activity has been documented for amprenavir [230] but
the clinical significance of polymorphisms in HIV-2 pol
for other PIs requires clarification [231]. Although currently there is no evidence to support interventions such
as Caesarean section or ART in women with HIV-2, they
should probably be managed in a similar way to HIV-1
infected women with low level viremia (e.g. zidovudine
with Caesarean section). If the mother has a high CD4
(4,300 cells/mm3) and a consistently undetectable HIV-2
viral load, even these interventions may not be necessary
[228]. The risk from breast milk is probably lower than
for HIV-1 but it may be advisable to avoid this method
of feeding. Although quantification of HIV-2 RNA is the
preferred method for monitoring disease and responses
to treatment, no commercial assays are currently available. Two laboratories in the UK can provide an HIV-2
viral load service:
Professor Judy Breuer/Tony Oliver
4th Floor Molecular Laboratory
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St. Bartholomew’s Hospital
Department of Virology
51–53 Bartholomew Close
West Smithfield
London EC1A 7BE, UK
Tel. 0207 6017359
Fax: 0207 3777259
Tel. Judy Breuer: 0207 3777141
E-mail: j.breuer@qmul.ac.uk
Tel. Tony Oliver: 0207 6017359
E-mail: tony.oliver@bartsandthelondon.nhs.uk
Professor Richard Tedder/Dr Jeremy Garson
Department of Virology,
Royal Free & University College London Medical
School
Windeyer Bldg. 46
Cleveland St
London W1T 4JF, UK
Tel. 0207 6799490/9483
Fax: 0207 5805896
E-mail: j.garson@ucl.ac.uk
The laboratory should be contacted first to discuss sample specimens and conditions for transporting.
Infants born to infected women should ideally be monitored for HIV-2 proviral DNA, samples should be referred to a specialist laboratory (see above). Determining
loss of HIV-2 antibodies by 12–18 months of age is also
recommended. In the absence of any studies on treatment of HIV-2 infection in children it is recommended
that guidelines for pediatric HIV-1 infection are followed
[232,233].

10.0 HIV and hepatitis virus B and C coinfections
10.1 MCT of HCV
•
•
•

All HIV-positive pregnant women should be tested
for HCV.
HCV-positive HIV-positive women should be treated
with combination ART.
PLCS should be offered to all coinfected mothers.

All women with HIV should be screened for both hepatitis B and C infection. Women with very low CD4 counts
may not produce a serological response to hepatitis C virus (HCV) and molecular assays to detect HCV RNA is
advised in this circumstance.
In women who are infected with the hepatitis C virus
(HCV) there is a low rate of transmission of HCV from
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mother to infant and current estimates indicate that up to
6% of women will infect their child [234–236]. The timing
and route of transmission is unclear and it is not known
whether transmission is trans-placental or during delivery. HCV plasma viral load is associated with transmission; women with undetectable viremia are highly
unlikely to transmit. HCV viremic mothers (HCV +/
HIV -) have an increased transmission rate of up to 10%
[235,237]. Some studies indicate that instrumental delivery may be associated with an increased rate of transmission and one study suggests that delivery by Caesarean
section may reduce the rate of transmission [234,238].
These data arise from relatively small scale, retrospective studies and the findings have not been confirmed.
Breast feeding is not thought to increase the risk of infection [234,236,238–240].
In women who are HCV and HIV coinfected, transmission is increased to up to 15%, with higher rates in those
who are HCV viremia [235,236,239,241]. Pappalardo’s
meta-analysis shows an increased odds ratio for HCV
transmission of 2.82 (95% CI 1.78–4.45) if the mother is
coinfected with HIV [242]. Effective control of HIV is associated with a reduction in the rate of HCV transmission although the mechanisms of this improvement are
unclear [243,244]. No studies to assess the benefits of surgical, rather than vaginal delivery, have been performed
in HIV-HCV-coinfected women.
Guidelines on the management of adults with HIV/
HCV coinfection per se can be obtained from the BHIVA
website
(http://www.bhiva.org/guidelines/2004/
HCV/index.html).
10.1.1 Diagnosis of infected children
In view of the increased risk of HCV infection in children born to women who are coinfected with HIV testing for HCV is recommended for all infants born to dually infected mothers. The optimal timing and nature of
the test that should be used is unclear. However, transmission of maternal antibodies is almost invariable and,
therefore, antibody testing is unreliable until the infant
is 15–18 months old. Testing for viremia during the first
few months of life may not reliably identify chronically
infected children and some studies suggest that a proportion of infants who are originally HCV RNA positive
will clear virus without intervention [234,238]. To identify chronically infected children repeat PCR testing for
HCV RNA should be performed during the first year of
life. A proportion of infected children do become HCV
RNA negative, so both serological and molecular tests
are important [245,246].
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10.2 MCT of HBV
•
•
•

•

All HIV-positive pregnant women should be tested
for HBV.
Infants born to women who are HBsAg positive
should receive active vaccination.
Infants born to women who are HBsAg positive and
HBeAg positive, as well as those with high levels of
HBV viremia should receive additional passive vaccination with HBIg.
ART for pregnant women with HIV/HBV coinfection should include drugs with activity against
HBV.

Maternal infection with the hepatitis B virus (HBV) is associated with a high incidence of transmission of HBV to
their infants. Transmission can be effectively prevented
by immunization of the at-risk infant shortly after birth
[245] and materno-fetal transmission of HBV has been
greatly reduced in developed countries by effective vaccination programs. Materno-fetal transmission of HBV is
related to the level of HBV viremia. In general women
who are HBeAg positive have a high incidence of transmission of HBV to their infants (90%) and the risk is reduced in women who are HBeAg negative (40%) [247].
However, women who are HBeAg negative with high
level hepatitis B viremia may have an increased incidence of materno-fetal transmission, although the magnitude of the increased risk and the precise level of viremia at which the risk becomes significant is not known.
Hepatitis B viral DNA quantification is, therefore, recommended for all HBsAg-positive mothers. It is standard practice in the UK to offer active vaccination to all
infants born to HBsAg-positive mothers and to offer passive vaccination with HBIg to children born to mothers
who are HBeAg positive. A Chinese study has demonstrated a reductioninvertical HBV transmission wheremothers received either the antiretroviral lamivudine or
hyper-immune globulin, compared with no treatment
[248]. Further studies to define the optimal treatment of
maternal disease as well as to prevent transmission are
required.
HIV may increase the serum HBV DNA levels and it is
plausible that coinfection will increase the rate of HBV
transmission. To date, no studies have reported an increase in the prevalence of materno-fetal transmission
of HBV in HIV/HBV coinfected patients. A single study
from Tanzania suggested that coinfection did not increase the risk of transmission but the study was small
and an increase in the rate of transmission cannot be excluded [249].
Some antiretroviral agents (e.g. lamivudine and tenofovir) are active against both HBV and HIV and in pregnant
women with HIV/HBV coinfection it may be appropriate to consider HAART regimes that include agents ac-
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tive against both HBV and HIV. Guidelines on the management of adults with HIV/HBV coinfection per se
can be obtained from the BHIVA website (http://www.
bhiva.org/guidelines/ 2004/HBV/index.html).
10.2.1 Diagnosis of HBV infection in children born to HBV
positive mothers
Infants born to HBV-positive mothers in the UK should
receive active HBV vaccination at birth and at 1 month,
2 months, and 12 months of age. Infants born to mothers
with high risk of infectivity should also receive HB immunoglobulin at birth. At 15–18 months of age infants
should screened for: (1) HBsAg, to confirm they have not
been infected; and (2) HBsAb to confirm that they have
responded to their vaccination.

11.0 Management of infants born to HIV-infected mothers
•
•
•

Most infants should be given Zidovudine monotherapy for 4 weeks.
Alternative suitable ART monotherapy may be given
if maternal therapy does not include ZDV.
Triple therapy should be considered for PEP for infants born to untreated mothers or mothers with detectable viremia despite combination therapy.

Most neonates born in the UK to mothers known to have
HIV will be exposed to ART in utero, during delivery

and after birth for the first 4–6 weeks of life. The range
of different combinations of ART to which neonates are
being exposed is constantly expanding. Neonatal drug
metabolism is generally slower than that of older infants
or children, and premature neonates have even less efficient metabolism [250]. Neonatal dosing regimens have
been developed for most of the nucleoside analogs, for
the NNRTI nevirapine, and for the PI nelfinavir. Studies
of dosing regimens for other drugs (e.g. Lopinavir/ritonavir and tenofovir) are planned or underway (Table 3).
Adequate neonatal blood levels are difficult to achieve
with Nelfinavir and there is little experience of other
PIs [251– 253]. The only ART available for IV use in sick
and/or premature neonates, unable to take oral medication, is zidovudine [254,255]. Reduced oral and IV dosing schedules for premature infants have only been developed for ZDV and these have been recently reviewed
with a new lower zidovudine dosing regime for premature babies [255]. A new simplified, dosing regime for
neonatal nevirapine use is suggested in these guidelines,
pharmacokinetic studies have demonstrated adequate
infant plasma levels with this regime [256]. This regime
is based on infant weight rather than surface area, and
was used in the study of prophylaxis of breast-fed infants once daily, for up to 6 months [257]. Neonatal metabolism of nevirapine is induced where there is antenatal in utero exposure [258,259], so if this drug is given
to the neonate, when the mother has taken it for more
than 3 days, then the full dose of 4 mg/kg/day should be
started at birth, rather than the induction dose (Table 4).
In view of the long half-life of nevirapine, if this is used
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in combination therapy for the infant, it should be
stopped 2 weeks before the other drugs to reduce the
risk of monotherapy exposure and development of resistance [171].
11.1 When to consider monotherapy ART for the infant after birth
Where a low transmission risk mother chooses ZDV
monotherapy with Caesarean section delivery, then the
infant should also receive zidovudine monotherapy.
Where a mother on triple combination therapy delivers
with a viral load of <50 copies/mL, our current practice
is to use single drug therapy for the neonate, as this is
practically easier for the family and may reduce the incidence of adverse events in the neonate. The drug chosen
from the maternal combination is usually the NRTI with
the best-known infant pharmacokinetics (e.g. ZDV, 3TC
etc.). With infant feeding patterns, it is difficult to separate drug dosing from feeds, so drugs without food restrictions are preferred and didanosine is avoided. Although, in a recent study with a higher neonatal dose
of didanosine high plasma levels were found [260]. Zidovudine should not be given to an infant born to a
mother who is receiving stavudine because of the theoretical negative competitive interaction. Development of
resistance mutations in women treated with zidovudine
monotherapy is rare in those on short-term treatment,
with low viral load and less advanced disease [11,261].
Transmission of zidovudine-resistant mutants to infants
has been reported, but is most common in mothers with
more advanced disease, higher viral loads and previous
and/or longer treatment with zidovudine monotherapy
[139,262–264]. Most of these transmissions occurred before the use of combination therapy for such higher risk
mothers. Monotherapy with nevirapine either to mother
or infant should be avoided because of the high rate of
development of resistance even with a single dose to
mother and/or infant [143].
11.2 When to consider combination ART in neonates
There have been very few studies of combination therapy in neonates and most are of only two drugs. There
are no published studies of efficacy of triple therapy in
neonates. Dual combination ART to the neonate (zidovudine + lamivudine vs. zidovudine) had additional benefits over single drug treatment (in historical controls) in
terms of reduction of transmission when mothers were
also receiving dual ART [125]. A randomized African
study which compared short course (1 week) treatment
to the infant with either zidovudine + nevirapine or NVP
also demonstrated superiority of two drugs (see below)
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[265]. However, in the randomized African ‘SAINT’
study, no significant difference in transmission rate was
demonstrated in short course treatment with either zidovudine + lamivudine or nevirapine after perinatal treatment to the mother [163].
There are three situations where triple combination
treatment for neonates should be considered: (i) postdelivery prophylaxis, where the mother is only found
to be HIV infected after delivery (Scenario 6); (ii) unplanned delivery, e.g. prematurely prior to starting ART;
or (iii) after a late presentation when details of maternal HIV parameters may not be available (Scenario 7).
Two studies have examined the first situation where due
to late diagnosis of the mother treatment could only be
given to the infant after birth. In a US cohort study a reduced risk of transmission, compared with no intervention, was observed in infants commenced on zidovudine
monotherapy provided this was started within 48 hours
of birth [transmission risk: complete 076 treatment – antepartum (AP), intrapartum (IP), and post-partum (PP),
6.1% (95%CI 4.1–8.9%); IP + PP, 10.0% (3.3–21.8%); PP
<48 hours, 9.3% (4.1–17.5%); PP >48 hours, 18.4% (7.7–
34.3%); no Rx, 26.6% (21.1–32.7%)] [154]. In a randomized African study of after-birth prophylaxis, babies born
to mothers presenting at delivery received either single
dose nevirapine or single dose nevirapine + a week of zidovudine [265]. At 6–8 weeks after delivery, the overall
MCT rate was 15.3% in 484 babies who received nevirapine + zidovudine and 20.9% in 468 babies who received
nevirapine alone (P 5 0.03). Of the babies who were HIVnegative on testing at birth, 34 (7.7%) who received nevirapine + zidovudine and 51 (12.1%) who received nevirapine alone were subsequently infected (P 5 0.03) – a
protective efficacy of 36% for the dual combination.
There have been no randomized studies of combination infant treatment after emergency delivery. Despite
this, it is logical to consider it appropriate for neonates,
as it is standard of care for any other postexposure prophylaxis cases, where the level of blood/body fluid exposure is likely to be much less [262].
We have used zidovudine, lamivudine and nevirapine
as combination therapy for infants born to drug naive
women, but for non-naive mothers other combinations
might be required if there is a possibility of resistance
(see above for details on stopping nevirapine). Resistance testing should be carried out in the mother in such
a situation and on the first positive sample of any infected infant.
11.3 Duration of antiretroviral treatment for neonates
In the PACTG 076 study zidovudine was administered
for 6 weeks after birth and this subsequently became

G u i d e l i n e s f o r t h e M a n a gm e n t o f HIV I n f e c t i o n i n P r e g n a n t W o m e n a n d t h e P r e v e m t i o n o f M o t h e r - t o -C h i l d T r a n s m i s s i o n o f HIV 131

standard of care [5]. However, in a Thai study, where a
short course of 3 days of neonatal treatment was compared to 6 weeks there was no increased transmission
where the mother received zidovudine from 28 weeks
gestation [153]. In the UK, neonates are currently treated
for 4–6 weeks but it is of note that current postexposureprophylaxis guidelines in other situations suggest treatment for 4 weeks only [266].

two zidovudine exposed children were shown to have
unexplained retinopathy and cardiomyopathy, which
could potentially be related to mitochondrial dysfunction [270]. A long-term follow-up study of health and development in ART-exposed children, by annual parental
questionnaire, is underway in the UK [277].

11.4 Side effects of treatment

Short-term, acute mitochondrial toxicity may rarely present in the newborn period, exacerbating the metabolic
stress of delivery. A small number of sick infants have
been reported with severe lactic acidosis, multisystem
failure and anemia, not attributable to any other cause;
all have recovered with supportive care [278]. Elevated
lactic acid levels have also been found in asymptomatic
ART exposed infants [279]. Neonatal anemia and neutropenia is reported in infants exposed to NRTIs, this may
be worse where there is exposure to combination therapy, or more prolonged treatment [125]. Transfusion is
rarely required and most children appear to respond to
discontinuation of marrow suppressive therapy. However, a more recent study of over 4,000 infants from the
French cohort has demonstrated that perinatal zidovudine may exert a small but significant, durable negative
effect on hematopoiesis up to the age of 18 months [280].
The mechanism and longer-term significance of this bone
marrow suppression is not known. An increased rate of
febrile seizures in antiretroviral exposed infants has also
been reported from the French perinatal cohort [281].
Whether different combinations of ART may be more or
less deleterious to the neonate is not known.
In view of the potential metabolic abnormalities reported with ART neonates exposed to ART should have
base line blood tests including: FBC, glucose, U + E, and
LFTs, as well as diagnostic HIV PCR tests. It is our practice to repeat these tests with each set of HIV diagnostic
samples. Lactate and pH monitoring for mitochondrial
toxicity should be undertaken in any symptomatic newborn but does not appear to be necessary in otherwise
well infants.

•
•
•
•

No evidence of any increase in congenital malformations in humans with first trimester exposure to any
antiretroviral therapy (including Efavirenz) to date.
Inadequate data to exclude a teratogenic risk for
most individual drugs and for all combinations.
Laboratory evidence of mitochondrial depletion in
infants exposed to ART perinatally but clinical importance uncertain.
Prolonged hematological (but not clinical) effects of
ZDV in exposed uninfected infants.

11.4.1 Long term
Long-term side-effects of perinatal exposure to ART can
be considered in four main categories: teratogenic, carcinogenic, developmental, and mitochondrial, but there
may be others not yet recognized [267]. Teratogenicity is
most likely to be a problem with first trimester exposure
to ART1 -other drugs. All currently licensed antiretroviral therapies (except efavirenz which has recently been
re-classified D) are classified either B or C for use in pregnancy by the FDA. All women who receive ART in pregnancy should be registered prospectively with the International Drug Registry (see below for details). To date,
no increase in total number, or any specific fetal abnormalities have been identified, but the voluntary reporting rate is disappointingly low. Detailed fetal anomaly
scanning at 18–21 weeks is advised after first trimester
exposure to any combination of ART. NRTI exposure
could theoretically lead to a long-term risk of carcinogenicity, although no increased rate has yet been identified
[268]. So far, no adverse growth or developmental effects
of ART exposure have been demonstrated in children
[269,270]. Mitochondrial toxicity after perinatal ART exposure, with two deaths from encephalopathy, was first
reported in uninfected infants from the prospectively followed French cohort [271]. Deaths have not been identified in other large cohorts [272–275]. However, laboratory analysis of mitochondrial DNA has demonstrated
abnormalities in infants born to ART treated mothers,
and this is an area of ongoing investigation [276]. In the
long-term follow-up of the infants from the 076 study,

11.4.2 Short term

11.5 Laboratory diagnosis of HIV infection in non-breast-fed
Infants
•
•
•
•

DNA PCR on at least two occasions off therapy.
Using primers known to amplify maternal virus.
Triple therapy in neonates can delay diagnosis of infection.
Document loss of maternal antibody at 18 months.

The gold standard test for HIV infection in infancy is
HIV DNA PCR on peripheral blood lymphocytes [282],
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although some studies are now demonstrating equal/increased early sensitivity with other amplification methods for viral RNA [283]. As most infants are infected intrapartum and blood levels may still be very low, HIV
DNA is not amplified from all infected infants at birth.
Indeed a positive HIV PCR result within 72 hours of
birth has previously been taken as evidence of intrauterine transmission [284]. Within the first weeks of life
the sensitivity of the test increases dramatically and by
3 months of age 95% 1 of non-breast-fed HIV-infected
infants will be detected. In view of the genomic diversity of HIV a maternal sample should always be amplified with the first infant sample to confirm that the primers used detect the maternal virus. If a maternal virus
cannot be detected by the HIV DNA PCR used then a
different primer set, or a different test (e.g. HIV RNA
PCR/NASBA/HIV culture) should be used [285,286]. It
is recommended to test infants at 1 day, 6 weeks, and 12
weeks of age. If all these tests are negative and the baby
is not being breast-fed, then parents can be informed that
the child is not HIV infected. Loss of maternal antibodies
is subsequently confirmed at 18 months of age. Evidence
from the French perinatal cohort has demonstrated that
neonatal ART, especially if more than one drug, can delay the detection of both HIV DNA and RNA in the infant [287]. For this reason, the second HIV DNA PCR is
collected at 6 weeks of age, after 2 weeks off treatment. If
an infant is found to be HIV infected after perinatal ART
exposure then the mother and infant should have urgent
HIV resistance testing to delineate the reasons for treatment failure and to help guide further treatment.
11.6 A managed network for children with HIV in the UK
Where an infant is found to be HIV infected, an urgent referral to the local specialist clinic should be made so that
early commencement of combination ART can be considered. HIV services for children in the UK are now being organized in managed networks. Perinatal HIV care
in London is managed within three clinical networks:
Northwest, Northeast and South London. Outside London there is a regional network for perinatal and pediatric HIV with each region linked to one of the three London lead centers. The details of the CHIN Networks and
contact details of the pediatricians can be found in the
CHINN report at http://www.bhiva.org/chiva [288].
11.7 Prophylaxis, immunizations and clinical monitoring
Primary pneumocystis pneumonia (PCP) in infants with
HIV remains a disease with a high mortality and morbidity [289]. However, as the risk of neonatal HIV infection
has fallen to <1% where mothers have taken up interventions, the necessity for PCP prophylaxis has declined
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and in most European countries it is no longer prescribed
routinely. However, Co-trimoxazole as PCP prophylaxis
should still be prescribed for infants born to mothers at
high risk of transmission (see Table 4 for dose).
Infants born to HIV-infected mothers should follow the
routine immunization schedule except that BCG vaccine
should not be given until the infant is confirmed uninfected, with two negative HIV DNA PCRs after 1 month
of age. Killed OPV is now recommended for all polio
vaccination in the UK regardless of HIV exposure.
Considering the importance of confidentiality, where
possible families should be strongly encouraged to inform primary health carers, including midwives, health
visitors and family doctors about maternal HIV and indeterminate infants. This will enable the local team to
give appropriate support and advice, especially regarding infant feeding and where an infant or mother is unwell.
11.8 Child protection
Rarely, pregnant mothers refuse treatment for their own
HIV as well as interventions to reduce the risk of transmission to their unborn infant. Where the multidisciplinary team is unable to influence a mother’s views, then
a prebirth planning meeting with Social Services should
be held. The mother should be informed that court permission will be sought at birth to treat the infant for 4
weeks with combination post-exposure prophylaxis and
in addition breast-feeding will be strongly discouraged.
On a practical note, it has been found that dealing with
each aspect of interventions to reduce MCT separately
and at the appropriate time has been helpful in some circumstances where for social or religious reasons mothers
have been reluctant to accept interventions for the prevention of MCT.
11.9 Reporting and long-term follow-up
It is the responsibility of clinicians caring for women with
HIV and their children to report women prospectively to
the UK National Study of HIV in Pregnancy and the International Drug Registry antenatally, and infants to the
British Paediatric Surveillance Unit (BPSU) after birth (see
below for details). Long-term follow-up of ART-exposed
infants is being undertaken via the Children Exposed to
ART (CHART) study [277]. The National Study of HIV
in Pregnancy and Childhood (NSHPC) is the UK surveillance system for obstetric and pediatric HIV, based at the
Institute of Child Health, London. Diagnosed pregnant
women are mainly reported through a parallel reporting
scheme run under the auspices of the Royal College of
Obstetricians and Gynaecologists. HIV-infected children
and children born to HIV-infected women are mainly re-
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ported through the British Paediatric Surveillance Unit of
the Royal College of Paediatrics and Child Health. For further information contact the co-ordinator of the NSHPC:
Dr Pat Tookey 0207 8298686, E-mail: p.tookey@ich.ucl.
ac.uk Antiretroviral Pregnancy Registry (in Europe
managed by GlaxoSmithKline), GlaxoSmithKline Ltd,
Green-ford Road, Greenford, UB6 0HE, UK. Tel. no: 020
89664500; Fax: 0208 9662338 http://www.apregistry.com

infant has been suggested as a possible site of entry
for the virus, but evidence to date is limited [293,294];
it seems biologically plausible that mixed feeding increases the risk of HIV transmission by making the gut
more susceptible through mechanical or inflammatory
mechanisms.

12.0 Infant feeding and HIV transmission during breast-feeding

More recent and reliable data, including the results of a
randomized clinical trial, confirm the substantial risk of
transmission through breast-feeding first highlighted in
the late 1980s and early 1990s. In the randomized clinical trial in Nairobi, HIV-infected pregnant women, none
of whom had received antiretroviral prophylaxis during
pregnancy, were allocated to either breast (n = 212) or artificial (n = 213) feeding [295]. Compliance with assigned
feeding modality was 96% in the breast-feeding arm and
70% in the formula arm. Median duration of breast-feeding was 17 months. The cumulative probability of HIV
infection at 2 years of age was 36.7% in the breast-feeding arm and 20.5% in the formula-feeding arm. The estimated absolute rate of transmission through breast-feeding over 2 years was thus 16.2%, approximately doubling
the overall rate of MCT to 39% at 2 years of age.
The rates of transmission through breast-feeding inferred from the cumulative rates over age in trials in
which a peripartum intervention to reduce MCT risk
was evaluated, are broadly in line with the results from
the randomized trial, with an increase in the estimated
percentage of infants infected between 4 and 6 weeks of
age and 18–24 months of 10–14% [162,163,167,296]. Differences between studies could be due to methodology
used to assess rate of transmission [297], variation in the
duration of breast-feeding between populations, as well
as to differences in maternal or other factors possibly associated with increased risk. In particular, there are considerable differences in maternal CD4 cell counts near
the time of delivery.

•

Recommend exclusive formula-feeding to all HIVpositive mothers.

Breast-feeding is an important route of transmission. In
the UK, where safe infant feeding alternatives are available, HIV-infected women are advised to refrain from
breast-feeding. If she is taking antiretroviral medication
it should be explained that currently there is no evidence
that this will protect the infant [290]. Although ART is
likely to reduce free virus in the plasma its effect on free
and cell-associated virus in the milk is not known.
12.1 Mechanisms of breast-feeding transmission
The level of HIV RNA in milk has only been studied on a
limited number of samples from HIV-infected mothers.
Generally, RNA viral load in milk appears to be lower
than in plasMA, USA, and frequently below the detection limit of current assays. In a study in South Africa
[291,292], RNA viral load was quantified three times in
the first 3 months after delivery, in samples taken from
both left and right breasts from 145 lactating women.
RNA shedding varied between breasts and over time
[291]. Milk viral load was below the limit of detection
of the HIV RNA PCR assay (<200 copies/mL) in a substantial proportion of samples, and milk viral load in the
first 14 weeks was highly variable and difficult to predict by maternal or infant factors. Low blood CD4 count
(<200/mL) during pregnancy and raised Na/K ratio (a
marker of subclinical mastitis) were significantly associated with increased milk RNA viral load at all times,
but there were no consistent associations between infant
feeding mode (whether exclusive or mixed breast-feeding) and RNA viral load in milk [292]. Together, the results of these studies indicate the random nature of virus
shedding into breast milk.
Sub-clinical mastitis in the mother is hypothesized
to increase ‘leakiness’ in the breast duct cell lining and
therefore increase the amount of virus to which an infant
is exposed [292,293]. Intestinal permeability of the young

12.2 Risk of MCT through breast-feeding

12.3 Late postnatal transmission
The risk associated with breast-feeding can best be estimated starting with young infants born to infected mothers who tested negative for HIV early in life, and to follow these children until after they cease breast-feeding
to determine their rate of acquisition of HIV infection
through breast-feeding.
In a recent meta-analysis, including data from more
than 4300 children enrolled in randomized controlled
trials of peripartum interventions in sub-Saharan Africa,
early transmission was defined by a positive HIV test before 4 weeks, and late postnatal transmission (LPT) by
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a negative diagnostic test at or after 4 weeks of age, followed by a subsequent positive test result. The overall
rate of transmission was 24% and of the 993 infected children, the timing of acquisition was early in 314 (31.4%),
late in 225 (23.1%) and unknown in 454 (45.4%). The
mean duration of breast-feeding was nearly 7 months,
and the median 4 months. Results show a continued risk
of LPT throughout the breast-feeding period, which was
approximately constant over time [298]. The cumulative
probability of acquiring HIV infection after 4 weeks of
age was 1.6% at 3 months, 4.2% at 6 months, 7.0% at 12
months and 9.3% (95% CI 3.8–14.8) at 18 months.

13.0 Interventions to reduce MCT of HIV–
clinical scenarios
Table 5 summarizes eight clinical scenarios, where a different approach to therapy in pregnancy may need to be
considered. The issues relating to each scenario are discussed in this section as well as other sections of the text.
The classification of levels of evidence and grades of recommendations are summarized in Table 6.
Pre-labor Caesarean section at 38 weeks is recommended as the mode of delivery in all scenarios where
the most recent viral load is detectable at 450 copies/ml
or where the viral load is unknown. Vaginal delivery
may be considered for women on stable therapy with an
undetectable viral load (<50 copies/ml) prior to delivery
as the risk of transmission is very low (<1%). However, it
is unclear from currently available data whether Caesarean section might lead to any additional benefit in reduction of HIV transmission from this low level. These uncertainties need to be discussed between the patient and
the medical and obstetric team in deciding on the individual birth plan.
13.1 Scenario 1–where mothers do not yet require treatment
for their HIV disease
Asymptomatic women who do not require antiretrovi-

ral treatment for their own health, according to current
BHIVA Guidelines (CD4 count is 4,200/mm [3], any viral
load) may be treated with a short-term ART (START) commencing in the second trimester with standard HAART
regimens with the intention to achieve undetectable viral loads of <50 copies/ml prior to delivery. A proteaseinhibitor based combination is recommended. PIs have a
greater barrier to resistance development than NNRTIs
and can be stopped concurrently with the nucleoside
backbone. In addition PI pill burden and tolerance is improving with newer formulations and there is a low incidence of severe short-term side-effects. If non-nucleosides
are used, these must be discontinued 1–2 weeks prior to
the nucleoside backbone–or switch the NNRTI to a shortacting PI before stopping the whole regimen–to reduce
the likelihood of the emergence of NNRTI resistance (see
Section 7.2.3, p. 23, BHIVA Adult Treatment Guidelines).
An alternative approach, in women who do not require
treatment for themselves, and who have a viral load of
less than 10,000 c/mL, is to use AZT monotherapy, combined with an elective Caesarean section. The risk of vertical transmission is low, and this reduces antiretroviral
exposure to the fetus in pregnancy. Maternal toxicity is
reduced and the risk of the development of resistance in
the mother, when used at this level of viral load, appears
minimal.
13.2 Scenarios 2, 3 and 4–women who required treatment for
HIV disease
It is recommended that women with any viral load
should be treated with antiretroviral regimens considered appropriated by BHIVA Guidelines for established
HIV infection. The pros and cons of these drugs are discussed above.
In treatment-naïve mothers requiring HIV therapy
(Scenario 2), consideration should be given to safety and
efficacy data available in pregnancy, tolerability and
whether treatment is likely to be continued after delivery.
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There is most experience in pregnancy with zidovudine
and lamivudine as the nucleoside backbone, which is
therefore usually recommended in combination with either a PI or a non-nucleoside drug (see Section 5).

lines for non-nucleoside regimens (see BHIVA Adult
Treatment Guidelines).

13.3 Scenarios 3 and 4–women who conceive on ART

Here, management would depend on optimum obstetric
management (e.g. use of antibiotics and steroids where
indicated) along with appropriate ART to the mother
and infant, according to the situation.

We now advise that these patients continue their current
treatment. Antiretroviral databases do not show an additional risk with this approach and there is also a theoretical concern that viral rebound will occur with this ‘structured treatment interruption,’ which might be associated
with a significant CD4 lymphocyte decline. This may not
only jeopardize maternal health but in theory result in
reactivation of infections associated with congenital abnormalities, e.g. cytomegalovirus. Furthermore, many
women will not realize or report their pregnant status
until well into the period of organogenesis. It is also recommended to continue with efavirenz as there are no
human data to suggest an increased risk of neural tube
abnormalities. Furthermore, switching to nevirapine as
an alternative NNRTI may risk additional toxicity in the
form of hepatitis or skin rash, particularly if the mother’s
CD4 count has been increased due to her prior ART.
If the mother’s treatment is failing, then this should be
changed appropriately to ensure the lowest possible viral
load at the time of delivery. Resistance testing can help
to identify the best options. Only exceptionally should
antiretroviral therapy be initiated or changed during the
first trimester. Reasonable exceptions include serious illness for which antiretrovirals are the only recognized
therapy.

13.5 Scenario 6–threatened premature delivery

13.6 Scenario 7–presentation of women after delivery
Where it is only ascertained after delivery that an infant
has been born to an HIV-infected mother, where maternal interventions have been declined or when interventions were introduced after labor had started, postexposure prophylaxis (PEP) should be offered as soon
as possible. There are observational data that zidovudine can reduce transmission in this situation if given
within 48 hours of delivery. Although there are no data,
it would seem logical and consistent with other PEP regimens recommendations for high-risk exposure to offer
triple-combination therapy for 4 weeks.
13.7 Scenario 8–mother of unknown status presenting (re-presenting) in labor

13.4 Scenario 5–women who present late in pregnancy

Attempts must be made to (re)discuss the HIV test and
if agreed perform a rapid test to determine the status.
Where results are delayed (or unknown) PEP (triple)
should be given to the infant according to standard risk
assessment procedures [265] (http://www.bashh.org –
Clinical Effectiveness Guidelines (CEG) for post exposure prophylaxis following sexual exposure).

With women who present very late in gestation or in labor, for whom no risk assessment has been possible, it
seems sensible to include compounds that rapidly cross
the placenta and have reliable pharmacokinetics in the
neonate. In this situation the most effective antiretroviral is nevirapine. PIs are not preferred because they have
limited trans-placental transfer. As always, combination
ART with at least two other drugs is recommended to
reduce the likelihood of resistance development as has
been shown with single-dose nevirapine monotherapy
during labor. Zidovudine should preferably be infused
IV, and all treatments should be continued after delivery
until the mother’s clinical, immunological and virological status has been determined. Consideration should be
given to continuing triple therapy until plasma viremia
has become undetectable. Therapy should subsequently
be discontinued in the manner recommended in guide-
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